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Adolescents and young adults represent a growing proportion of people living with HIV around 
the world and have worse outcomes than all other age groups. Retention along each step of the 
HIV care cascade is essential for optimal care, but importantly, achieving sustained adherence to 
antiretroviral therapy (ART) and subsequent viral suppression is necessary for decreasing 
morbidity and mortality and reducing further transmission. The overarching goal of this 
dissertation was to assess health-services interventions aimed at improving ART adherence 
among adolescents and young adults living with HIV, and prospectively evaluate one such 
intervention – point-of-care viral load testing – in a randomized control trial. 
 
First, a systematic review was conducted to assess and synthesize recent research on 
interventions aimed at improving ART adherence among adolescents and young adults living 
with HIV in a resource-limited setting. Evidence from the review indicated that comprehensive 
models of HIV care, re-structuring how HIV services were delivered to patients, which included 
increased monitoring of adolescents and young adults through home visits or case management 
in addition to standard clinical care improved ART adherence. Second, a randomized control 
trial was conducted to evaluate the implementation and effect of point-of-care viral load testing 
compared to standard laboratory-based testing. The trial had two primary objectives: 1) to assess 
the efficiency of point-of-care viral load testing, and 2) evaluate the effect of point-of-care viral 




protocol is described including study design, the point-of-care viral load testing intervention, 
analysis plan, and outcome definitions. Lastly, the results of this trial are reported which indicate 
that point-of-care viral load testing can be feasibly integrated into a low-resource, clinical 
setting. A majority of point-of-care viral load test results (81.8%; 148/181) were processed and 
returned the same day, with a mean time between blood collection and participant receipt of 
results of 2.7 hours (IQR: 2.5-3.2; range 1.7-6.0). Point-of-care viral load testing also appeared to 
improve the accuracy of reported ART adherence, an unanticipated finding. In the point-of-care 
arm, participants who reported sub-optimal ART adherence on any of 3 adherence questions 
were more likely to have a VL >1,000 copies/mL (OR: 6.57; 95% CI: 2.12-25.21), compared to 
participants in the standard arm among whom the association was weaker (OR: 2.62; 95% CI: 
0.97-7.44). There was no difference in viral load outcomes between arms.  
 
Overall, this dissertation addresses gaps in our knowledge about interventions aimed at 
improving ART adherence among adolescents and young adults living with HIV. The key 
finding is that point-of-care viral load testing can simplify the viral load monitoring process and 
help clinicians accurately identify adolescents and young adults with a high viral load in order to 
provide enhanced adherence counseling or make clinical decisions regarding appropriate 
treatment options faster. Point-of-care viral load testing could be used in concert with other 
interventions which address additional barriers to ART adherence among adolescents and young 
adults such as forgetfulness, stigma, or lack of social support. As the public health field 
continues to focus on improving HIV outcomes among this vulnerable age group, these findings 




which could increase the number of adolescents and young adults who achieve sustained ART 
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CHAPTER 1: INTRODUCTION 
1.1 Background  
Adolescents and young adults living with HIV are a highly vulnerable and underserved 
population. Deemed ‘the center of the HIV epidemic’, adolescents and young adults have worse 
outcomes than all other age groups (1-3).  In 2018, 510,000 young people between the ages of 10 
and 24 years were newly infected with HIV (4). In addition to heterosexual transmission, a 
generation of children who acquired HIV at birth are now aging into adolescence, adding to the 
burden of disease in this age group. Access to antiretroviral therapy (ART) has increased, 
making it increasingly possible to manage HIV disease over the long-term. With the appropriate 
regimen and perfect adherence, ART serves to re-establish immunological function, prevent 
further morbidity and mortality, and curb further HIV transmission. However, adolescents and 
young adults have poorer ART adherence than all other age groups and are less likely to achieve 
viral suppression than both children and adults (1, 5). 
 
Adolescence and early adulthood is an inherently high-risk developmental period when decision-
making, long-term planning skills, and sense of personal risk are not highly developed, 
contributing to persistently poor outcomes. As adolescents and young adults are still developing 
cognitively, socially, and emotionally, they often underestimate harmful consequences and long-
term effects of decisions (6). They are faced with choices regarding relationships, sexual 
behavior, and alcohol and drug use (7-9). They lack financial autonomy, are prone to external 
pressures and coercion, and lack problem-solving skills (10-14). Further, in resource-poor 
settings, external factors including poverty, food scarcity, unstable home-life, and HIV-related 
stigma acutely influence adolescent behavior which impacts retention in care, ART adherence, 




are a high-risk population prone to marginalization from routine healthcare access and require 
tailored interventions to improve health outcomes. Optimizing the delivery of HIV services 
which respond directly to young people’s specific needs could have a direct impact on improving 
ART adherence and ultimately viral suppression among this vulnerable age group. 
 
1.2 Existing Evidence 
Many factors contribute to poor treatment adherence for a chronic illness (23-27). Adherence to 
HIV treatment is compounded by the added complexity of HIV-related stigma (28-31). The 
heightened vulnerability of the adolescent/early adulthood developmental stage adds another 
layer of challenges. Adolescents report having the same difficulties as adults in adhering to a 
complex daily regimen and experience similar barriers, but have less autonomy and lower 
developmental capabilities, putting them at higher risk of non-adherence (12, 32). Major barriers 
to ART adherence include patient-related factors, medication-related factors, and factors related 
to health services, with the latter being the least prevalent in the adolescent HIV literature.  
 
A majority of research related to ART adherence in adolescents and youth consists of identifying 
barriers rather than testing interventions to address them. Recent systematic reviews have found 
no conclusive evidence-based interventions which improved adolescent and youth ART 
adherence (20, 33-35).  Few nonrandomized prospective pilot studies and randomized controlled 
trials have been published. Overall, interventions which address health-services based barriers 






1.3 Rationale  
Routine viral load monitoring is a critical service which could improve ART adherence. An HIV 
viral load can guide clinical decision-making for changing treatment regimens; early indication 
of treatment failure can prevent health deterioration and poor health outcomes (36-38). Research 
shows that compared to exclusive clinical observation, the assessment of therapeutic success of 
an ART regimen is most effective through laboratory viral load monitoring (39). Viral load also 
measures infectivity which can indicate a patient’s risk for further transmission. Since 
adolescents and young adults are at high risk for non-adherence, for failing treatment, and for not 
achieving viral suppression, optimizing viral load testing and minimizing the steps to returning 
viral load results could be an opportunity to improve health outcomes. 
 
Routine viral load tests are recommended at 6 month intervals until viral suppression is achieved 
and then annually (40, 41). Viral load is measured by FDA-approved molecular tests that amplify 
HIV RNA by polymerase chain reaction (PCR). The approved assays require high laboratory 
capacity including separate systems of extraction and amplification of the viral genome, 
technical expertise, and high equipment and maintenance costs (42). At high cost, robotic and 
other automatic technologies can allow high throughput which is efficient for large central 
laboratories, however, smaller laboratories or clinics without this level of laboratory capacity do 
not benefit from these technologies. Thus, the requirements for laboratory-based viral load 
testing are often incompatible with available resources in resource-limited settings where 
sophisticated instrumentation, dedicated large laboratory space, and highly-trained technicians 
are in short supply. Laboratory testing also requires coordinated transportation of specimens 




samples to a central laboratory risks significant delays and mis-placed or lost samples and results 
(43, 44). The greater the time between testing and returning results, the greater the potential for 
loss of patients from HIV care.    
 
New technologies allow viral load to be measured in automatic systems that can be placed at the 
point of care. The objective of point-of-care technologies are to simplify testing and make it 
faster to obtain results while retaining the accuracy and precision of laboratory-based testing. 
Testing at the point of care removes the logistical complexity of transporting specimens to a 
centralized laboratory, processing samples away from the clinical site, and returning results to 
the provider – all steps which increase the amount of time between testing and receiving the 
results – critical time during which patients could be lost to follow-up or in which disease 
progression could worsen without appropriate clinical management. Point-of-care technologies 
address some of the major barriers that centralized laboratory-based testing pose in resource-
limited settings: lack of laboratory capacity, lack of reliable transportation, lack of coordinated 
laboratory and clinical services to successfully track specimens and results, and lack of highly 
trained laboratory personnel.   
 
In addition to logistical simplicity, point-of-care viral load testing could impact future ART 
adherence and subsequent viral suppression because it makes an immediate connection between 
behavior and potential for negative health outcomes, a concept that is often lacking during the 
developmental stage of adolescence. As adolescents develop cognitively, they are still 
transitioning from concrete thinking to abstract thinking and they may lack the conceptual 




regimen (27, 45, 46). When adherence is evaluated, a blood test is taken, and the test result is 
returned in the same visit, concrete results – poor viral load test results as a result of poor ART 
adherence – are given, and interventions to improve adherence can be implemented immediately. 
Faster results and subsequently strengthened counseling could have a stronger impact to motivate 
future improvements in adherence. 
 
1.4 Dissertation Outline 
The overarching goal of this dissertation is to assess interventions aimed at improving ART 
adherence among adolescents and young adults living with HIV in a resource-limited setting. I 
specifically evaluate the implementation and effect of one such health-services intervention – 
point-of-care viral load testing, compared to standard laboratory-based viral load testing in a 
randomized control trial conducted in Haiti. 
 
The ground work and idea for this dissertation topic was developed as a result of previous 
research I conducted in Haiti among adolescents and young adults living with HIV. In a 
retrospective cohort study, I evaluated outcomes along the HIV care cascade before and after 
establishing a specialized adolescent HIV clinic which showed that the clinic improved the 
proportion of adolescents who enrolled in HIV care and initiated ART, but had no effect on long-
term retention in care (47). This study was the impetus for the development and evaluation of an 
intervention among adolescents and young adults to improve long-term retention in HIV care. In 
a new model of HIV care, cohorts of 5-8 young people met monthly for integrated clinical care, 
counseling, and social activities to address issues of social isolation, family rejection, and HIV 




receiving standard HIV care, an absolute increase of 20% retained in care (48). However viral 
suppression outcomes remained suboptimal with just 26% of participants achieving a viral load 
<1,000 copies/mL, which prompted my interest to focus this dissertation on improving this last 
step of the HIV care cascade – ART adherence and viral suppression. 
 
This dissertation is comprised of five chapters. This introductory chapter outlines the rationale 
behind the point-of-care intervention we elected to evaluate and our hypotheses about its 
potential effect on the viral load monitoring process and participant health outcomes. Chapter 2 
is a systematic review of the literature to assess existing interventions to improve ART adherence 
among adolescents and young adults. Building off a comprehensive review of literature 
published between 2003 and 2015 which identified 10 studies evaluating interventions to 
improve ART adherence in this age group, all which were conducted in developed countries 
(49), this systematic review focuses on studies published between 2016 and 2019 which were 
conducted in a low- or middle-income country. 
 
Chapter 3 describes the protocol for the randomized control trial I designed and led to evaluate 
point-of-care viral load testing compared to standard laboratory based testing among adolescents 
and young adults ages 10-24 years living with HIV in Haiti. A randomized design was chosen 
since existing research on health-services interventions are limited to prospective pilot studies 
without a control group, or programmatic evaluations using routinely-collected patient-level data 
which lack sufficient data on potential confounders, and importantly, lack definition of the 
intervention which limits accurate measurement of the impact and the ability to reproduce or 




Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections, which is located in Port-
au-Prince, Haiti and where preliminary research for this dissertation was conducted. The protocol 
describes details of the study design, how the point-of-care viral load testing intervention was 
implemented, study activities, data collection procedures, outcomes and measurements, and 
analysis plan. A randomized trial fills a knowledge gap by evaluating a health-services 
intervention, uses a randomized control group to account for potential confounders, and directly 
addresses issues such as transportability of impact and feasibility of implementation in other 
similar settings which aren’t easily accounting for when using other study designs. 
 
In Chapter 4, the results of the trial are reported. A description of the viral load testing process is 
provided comparing point-of-care to standard laboratory-based viral load testing including 
details of the time between blood collection and receipt of the result, and reasons for any failures 
to process a test or return a result. Describing the implementation process serves to indicate the 
feasibility of introducing a point-of-care viral load testing protocol in a low-resource, clinical 
setting, and among an adolescent and young adult population. Additional outcomes including 
ART adherence and viral load, 6 months from receiving a viral load test, are compared by arm.  
 
Chapter 5 presents an overall summary of the dissertation findings including a discussion about 
implications for scale-up of point-of-care viral load testing, and future directions for the public 
health field in its efforts to improve ART adherence and viral suppression among adolescents 
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Introduction: Adolescents and youth living with HIV have poorer antiretroviral treatment 
(ART) adherence and viral suppression outcomes than all other age groups. Effective 
interventions promoting adherence are urgently needed. We reviewed and synthesized recent 
literature on interventions to improve ART adherence among this vulnerable population. We 
focus on studies conducted in low- and middle-income countries (LMIC) where the adolescent 
and youth HIV burden is greatest.  
Methods: Articles published between September 2015 and January 2019 were identified through 
PubMed. Inclusion criteria were: 1) included participants ages 10-24 years; 2) assessed the 
efficacy of an intervention to improve ART adherence; 3) reported an ART adherence 
measurement or viral load; 4) conducted in a LMIC. Articles were reviewed for study population 




Strength of each study’s evidence was evaluated according to an adapted World Health 
Organization GRADE system. Articles meeting all inclusion criteria except being conducted in 
an LMIC were reviewed for results and potential transportability to a LMIC setting. 
Results and discussion: Of 108 articles identified, 7 met criteria for inclusion. Three evaluated 
patient-level interventions and four evaluated health services interventions. Of the patient-level 
interventions, two were experimental designs and one was a retrospective cohort study. None of 
these interventions improved ART adherence or viral suppression. Of the four health services 
interventions, two targeted stable patients and reduced the amount of time spent in the clinic or 
grouped patients together for bi-monthly meetings, and two targeted patients newly diagnosed 
with HIV or not yet deemed clinically stable and augmented clinical care with home-based case-
management. The two studies targeting stable patients used retrospective cohort designs and 
found that adolescents and youth were less likely to maintain viral suppression than children or 
adults. The two studies targeting patients not yet deemed clinically stable included one 
experimental and one retrospective cohort design and showed improved ART adherence and 
viral suppression outcomes.  
Conclusions: ART adherence and viral suppression outcomes remain a major challenge among 
adolescents and youth. Intensive home-based case management models of care hold promise for 





Adolescents and youth, 10 to 24 years of age, represent a growing proportion of people living 
with HIV around the world and have worse outcomes than all other age groups (1-6). In recent 
years, AIDS-related deaths among adolescents and youth increased by 50% while they have 
decreased among all other age groups (7). In 2018, 510,000 young people between the ages of 10 
to 24 years were newly-infected with HIV, 40% of whom were between 10 and 19 years of age 
(8). In addition to heterosexual transmission, a generation of children infected with HIV 
perinatally are now aging into adolescence, adding to the burden of disease in this age group.  
 
Adequate adherence to an antiretroviral therapy (ART) regimen leading to viral suppression is 
essential for an adolescents’ own health and well-being, and to reduce further HIV transmission. 
Yet, adolescents and youth have poor adherence to drug regimens for many chronic illnesses (9-
12). Adherence to ART is further complicated by HIV-related stigma (13-16). The period of 
adolescence and youth is characterized as a time of great physiological and psychological growth 
and development (1, 17), increased desire for independence from parents (18), and increased 
risk-taking (19), adding another layer of complexity. During this developmental stage, initiation 
of sexual activity is common and may include early pregnancy (20). Adolescents and youth also 
lack financial autonomy, are prone to peer pressure, and lack problem-solving skills (21-25). 
Further, in resource-limited settings, external factors including poverty, food scarcity, and HIV-





Major barriers to ART adherence for adolescents and youth can be divided into 3 categories: 
patient-level factors (e.g. socioeconomic status, stigma) (34, 35), health services factors (e.g. 
clinic waiting times, drug availability, quality of care) (36, 37), and medication factors (e.g. 
dosing, high pill burden, side effects) (3, 38, 39). Much of the research on ART adherence 
among young people has focused on identifying and estimating the prevalence of these barriers 
(29, 33, 38, 40, 41). A comprehensive review of the literature between 2003 and 2015 identified 
10 studies which evaluated interventions to improve adherence in adolescents in developed 
countries (42). Effective interventions included daily interactive text reminders for dosing (43, 
44), and computer-driven support programs (45). However, none of the studies included were 
conducted in a low- or middle-income country (LMIC) (46), areas where the global HIV 
epidemic is centered. Further, most of these studies were descriptive reports or pilot studies with 
small sample sizes and thus had insufficient power to detect meaningful effects.  
 
Given the critical need to identify effective approaches to improve outcomes among adolescents 
and youth living with HIV, we evaluated and synthesized the recent published literature on 
research conducted in a LMIC aimed at improving ART adherence in this population. 
 
2.3 Methods 
Article Search and Selection 
We searched the PubMed database for English language articles which evaluated interventions to 
improve ART adherence among adolescents and youth living with HIV, conducted in a LMIC, 




Figure 2.1 (47). We then manually reviewed the references sections of relevant articles. Records 
were managed using EndNote and duplicates were removed manually. One reviewer (LR) 
conducted the primary search and articles selected for inclusion were approved by all authors. 
Articles selected met the following criteria: 1) included adolescents and youth ages 10-24 years; 
2) evaluated an intervention to improve ART adherence; 3) included an ART adherence 
measurement outcome (self-report, pill count, or medication event monitoring systems (MEMS)) 
or viral load (VL) as a proxy for an adherence measurement; 4) conducted in a LMIC. Eligible 
manuscripts were not restricted by study design and included studies which evaluated structural, 
behavioral, or health services-related interventions aimed at improving ART adherence.  
 
Data Extraction and Synthesis 
Each of the articles meeting our inclusion criteria was reviewed for characteristics of the study 
population (e.g. age, time on ART, health status at baseline), type of intervention evaluated, 
study design, outcome measured (ART adherence or VL), and intervention efficacy. The strength 
of each study’s evidence was evaluated according to an adapted GRADE system utilized by the 
World Health Organization (48). This system classifies studies into four levels based on study 
design, analysis plan, and existence of comparison groups. High quality evidence (level 4) are 
randomized control trials (RCT) with statistical testing comparing groups. Moderate quality 
evidence (level 3) are prospective cohort studies with statistical testing comparing groups. Low 
quality evidence (level 2) are retrospective or descriptive studies with statistical testing of 
between or within group comparisons; and very low quality evidence (level 1) are studies 




Due to the small selection of studies and diversity of outcome measures, a meta-analysis was not 
conducted to synthesize the effect size across studies. We reviewed the seven included studies to 
determine interventions with the most potential for impact and assessed areas in need of further 
research and evidence. 
 
2.4 Results 
Included Studies and Populations  
The PubMed search identified 1,229 articles, of which 1,121 were excluded based on review of 
the abstract. A full text review was completed on 108 articles. Seven studies met the inclusion 
criteria. Reasons for exclusion are listed in Figure 1; if an article was excluded for failing to meet 
more than one criteria, it is listed under the first exclusion category as prioritized in the criteria 
above. The most common reason for exclusion was only including participants outside the age 
range of interest (10-24 years) or reporting outcomes which were not disaggregated so as to 
discern results among adolescents and youth (i.e. results reported for ages 18-29 years). The 
seven studies meeting our inclusion criteria are described in Table 2.1. All were conducted in 
sub-Saharan Africa and included adolescents living with HIV who were aware of their HIV 
status and were receiving HIV care at a health facility. The median sample size was 702 (range 
94-6,706).  
 
We also reviewed and report the results of 4 articles that were excluded because the studies were 
not conducted in a LMIC. We briefly summarize the results of these studies here and their 




our primary goal was to identify interventions which would be directly applicable in resource-
limited settings where the global HIV burden among adolescents and youth is greatest. 
 
Intervention Types  
Studies either focused on: (1) patient-level interventions, i.e. interventions implemented at the 
individual level in addition to standard HIV care (n=3); or (2) health services interventions which 
re-structured the way HIV care was provided, also called ‘models of HIV care’ (49, 50) (n=4).  
 
In the first patient-level intervention, a once-weekly SMS text message was designed to check-in 
with participants about their general well-being (51). One study arm received this weekly check-
in message but could not respond to the sender. The second arm received the same message and 
could respond to the sender. The third study arm received standard care, i.e. no messages. The 
second study evaluated an economic intervention in which a savings account was established 
which could be used for small business development or education, i.e. school fees or lunches to 
address financial-related barriers to ART adherence (52). In the third study, three consecutive 
monthly individual intensive adherence counseling sessions were provided to participants. The 
goal of the sessions was to identify adherence barriers and develop individualized plans to 
address them (53). 
 
Four studies evaluated health services interventions which are categorized as either less intensive 




reduced the amount of time stable participants spent in the clinic. In the first, multi-month ART 
prescriptions allowed participants to come to the clinic less frequently ranging from every other 
month and some only twice per year for medication refills and clinical check-ups (54). In the 
second, a group-based model of care, patients formed groups of 25-30 participants and met every 
other month for group counseling, brief check-ups, and distribution of ART refills (55). Groups 
were facilitated by a lay health worker and nurse and met at a health facility or community 
venue.  
 
Two studies of more intensive models of care targeted newly diagnosed adolescents initiating 
ART or those who had not yet been defined as adherent or stable. These two models of care 
augmented regular care with additional support through home-based case management by a 
community health worker (56) or peer counselor (57). In the first, a community-based support 
worker (i.e. lay health worker) made weekly home visits to provide additional individualized 
adherence support. As participants became stable, frequency of home visits decreased to monthly 
and then quarterly, but increased again in the event of any clinic visit lapses (56). In the second, 
peer counselors (i.e. trained adolescents and youth ages 18 to 24 years living with HIV) referred 
to as ‘community adolescent treatment supporters’ provided adherence counseling and 









Study Design, Outcomes, and Participant Eligibility 
Of the three studies which evaluated patient-level interventions, two used experimental designs 
and one entailed a retrospective cohort study. The study evaluating text messaging used a 3-arm 
RCT to compare text messaging and text messaging with the option to respond to standard care 
(no text messaging). The primary outcome was mean ART adherence over the 48-week study 
period which was measured using medication event monitoring systems (MEMS) and defined as 
the ratio of recorded bottle openings to the number of prescribed bottle openings (51). Eligible 
patients were 15 to 22 years of age, in care at an HIV care facility, and prescribed ART. The 
study evaluating a participant savings account used a 2-arm RCT comparing the intervention to 
standard care. The primary outcome was VL <40 copies/mL 24 months after study enrollment 
(52). Eligible patients were ages 10 to 16 years of age, in care at an HIV care facility, and 
prescribed ART. The study evaluating monthly intensive adherence counseling sessions used a 
retrospective cohort design and no comparison group. The primary outcome was VL <1000 
copies/µl measured within 180 days of completing the 3 sessions (53). Eligible patients were 
ages 10 to 19 years of age, in care at an HIV care facility, prescribed ART and had a VL >1000 
copies/mL. 
 
Intervention Effectiveness  
None of the interventions in the three studies significantly improved ART adherence or VL 
outcomes in their primary analyses (all GRADE level 4). SMS text messaging did not 




prescribed doses taken) was 64% in the group that received text messages (p=0.27 compared to 
control), 61% in the group that received text messages with the option to respond (p=0.15 
compared to control), and 67% in the control group (51). The study comparing participant 
savings accounts to standard care also showed no statistically significant difference in viral 
suppression between arms. The proportion of participants with a VL <40 copies/mL at 24 
months did not significantly differ by arm – 65.9% in the intervention arm and 63.4% in the 
control arm (52). The observational study of intensive adherence counseling also observed low 
rates of VL suppression post-counseling. Among 192 adolescents included in the study, 117 
(60%) had a repeat VL measurement after 3 counseling sessions and 34/117 (29%) achieved a 
VL <1000 copies/mL (53).  
 
Health Services Interventions 
Study Design, Outcomes, and Participant Eligibility 
The four studies evaluating health services interventions included three retrospective cohort 
studies and one RCT. The study evaluating multi-month ART prescriptions was a retrospective 
cohort study and used programmatic data to report outcomes of children and adolescents who 
transitioned to this less intensive model of care after they were deemed clinically stable and ART 
adherent, defined as having an improving CD4+ cell count or CD4% or a VL <400 copies/mL 
and pharmacy pill count >95%. The primary outcome – VL <400 copies/mL – was compared 
between age groups (<1 year, 1-4 years, 5-9 years, 10-14 years, and 15-19 years) (54). The 
group-based intervention study evaluating community-based adherence clubs was a retrospective 




months, and had 2 consecutive VL measurements <400 copies/mL. Outcomes were maintaining 
a VL <400 copies/mL and viral rebound at 12 months from enrollment and were compared 
between age groups (16-24 years and >25 years) (55). Since eligibility for both of these studies 
required established ART adherence and clinical stability, these evaluations aimed to determine 
if adolescents and youth could maintain a stable status after shifting to a less intensive model of 
care. 
 
The two studies of health service interventions which evaluated a more intensive model of care – 
home-based case management in addition to regular clinical care – included one retrospective 
cohort study and one RCT. The study evaluating the community-based support worker 
intervention examined a retrospective cohort of adolescents and youth ages 10 to 24 years who 
were newly diagnosed with HIV and were ART-naïve. Outcomes included mean medication 
possession ratio (ratio of days of dispensed medication to days between pharmacy visits) and VL 
<400 copies/mL assessed at 3 and 5 years from initiating ART. Outcomes were compared to 
participants who did not receive support over the same 5 year study period (56). The study 
evaluating community adolescent treatment supporters was a two-arm RCT among adolescents 
ages 10 to 15 years who were in care at an HIV care facility and prescribed ART. Participants 
were randomized to the treatment supporter intervention or standard care and the primary 








Both studies of less intensive models of care – multi-month ART prescriptions (54) and group-
based care (55) – showed a relatively high proportion of adolescents and youth maintained a VL 
<400 copies/mL over study follow-up (75% and 97.2%, respectively) (GRADE level 2). 
However in both studies, compared to children and adults, adolescents and youth were at higher 
risk for viral rebound (i.e. VL >400 copies/mL). In the study evaluating multi-month 
prescriptions, at baseline approximately 85% of children (ages 1-9 years) and 80% of adolescents 
(ages 10-19 years) had a VL <400 copies/mL. Over 60 months of follow-up with annual VL 
measurements, this proportion remained steady among children, but decreased among 
adolescents to approximately 75% (54). In the study of community-based adherence clubs, the 
proportion of adolescents (ages 16-24 years) retained in care at 12 months was significantly 
lower than that observed among adults (ages >25 years) – 90.9% vs. 94.1%, respectively 
(p=0.022). Among those retained in care, the proportion of participants with VL <400 copies/mL 
was similar – 97.2% of adolescents and 98.0% of adults (p=0.194) – but in adjusted analyses, 
adolescents were at significantly higher risk of experiencing viral rebound compared to adults 
(adjusted hazard ratio: 2.24; 95% CI: 1.0-5.04) (55).  
 
The two studies examining intensified models of care – home-based case management (56, 57) – 
were the sole studies included in our review which improved ART adherence and viral 
suppression. The community-based support worker intervention which involved home visits by a 
lay health support worker, found that 5 years from initiating ART, 81.2% of participants 
receiving the support intervention achieved a VL <400 copies/mL compared to 62.8% among 




level 4). In the RCT examining the community adolescent treatment supporter intervention 
which involved home visits from a peer counselor also living with HIV, 12-months from study 
enrollment, 71.8% of participants in the intervention arm self-reported ART adherence compared 
to 39.3% receiving standard care (p<0.05) (GRADE level 3).  
 
Additional Studies in High Income Countries 
There were four additional studies which met inclusion criteria but were conducted in high 
income settings. Two studies evaluated intensive individual or group counseling in the United 
States. The Positive Strategies to Enhance Problem-Solving Skills (STEPS) intervention 
consisted of five one-hour counseling sessions rooted in cognitive-behavioral theory and 
motivational interviewing skills administered by a master’s or doctoral-level clinician (58). In a 
pilot RCT including participants self-reporting <90% adherence at baseline, 14 participants were 
randomized to the STEPS intervention or standard care. After 4 months, mean ART adherence 
among participants randomized to STEPS increased by 13%, and decreased by 26% among 
participants randomized to standard care, measured by MEMS data. No statistical comparison 
was conducted for this pilot RCT. The ACCEPT intervention was a group-based educational 
intervention including topics on stigma, disclosure, healthy relationships, and life planning (59). 
In an RCT including 103 adolescents and youth newly diagnosed with HIV, participants in the 
ACCEPT intervention arm had a 2.33 greater likelihood of self-reported ART adherence at 12 





Two studies evaluating technology-driven interventions showed statistically significant 
improvements in VL suppression. In a prospective cohort study conducted in Argentina, an 
intervention of twice-monthly private messaging through social media was evaluated among 
adolescents and youth with 2 consecutive VL measurements >1000 copies/mL. Twenty-two 
participants were enrolled and at 32 weeks, 64% achieved a VL <1000 copies/mL (60). An RCT 
conducted in the United States included 66 participants ages 14-26 years with a detectable VL at 
baseline and evaluated an iPhone game designed around themes of ‘fighting’ or ‘destroying’ 
HIV in the body by taking ART. After 16-weeks, among participants who had newly initiated 
ART, the decrease in mean log VL of participants in the intervention arm (3.63-0.93) was 
significantly greater than the decrease in mean log VL of participants in the control arm (3.94-
1.53) (p=0.04) (61). 
 
2.5 Discussion 
This systematic review identified seven studies published between 2015 and 2019 which 
evaluated a patient-level or health service intervention to improve ART adherence among 
adolescents and youth living with HIV ages 10-24 years in a LMIC. This expands upon a prior 
review of the same topic examining studies published between 2003 and 2015 (42), none of 
which were conducted in a LMIC. Among the seven studies in our review, three employed 
experimental designs appropriately powered to detect intervention effects, and five included a 
VL outcome, an objective biomarker of adherence (31). The increase in the number and location 
of studies observed compared to the earlier review indicates a positive shift of focus to identify 




quality evidence should be emerging soon from four ongoing RCTs we identified, two from sub-
Saharan Africa (62-65).  
 
The outcomes of the interventions evaluated indicate that ART adherence and viral suppression 
among adolescents and youth remain a major challenge. None of the three studies evaluating 
patient-level interventions, including two RCTs contributing high-quality evidence, showed 
improvement in either outcome. Adolescents and youth face a variety of barriers to ART 
adherence, which evolve as they develop physically, emotionally, and socially. Interventions 
designed to target a single, specific challenge, such as forgetfulness, may be insufficient. For 
example, the text message intervention was very narrow in scope – no additional counseling was 
done via text message and the messages were only sent weekly, so did not serve as a daily 
reminder for taking ART medication. Further research on combination interventions such as 
incorporating text messaging within a larger package of services is warranted, particularly as 
such combination intervention strategies have been effective among adults (66, 67).   
 
The majority of studies reviewed focused on how HIV services were delivered to adolescents or 
youth (54-57). The two studies on less intensive models of care indicated that adolescents and 
youth may be less likely to remain clinically stable as they were more likely to experience viral 
rebound than children or adults in both studies. Additional studies show that among adolescents 
and youth who do achieve VL suppression, only 50% maintain this for one year (68). Given 




factors, and adolescents and youth are known to have suboptimal viral suppression outcomes, the 
concept of ‘stable’ adolescents and youth may be misleading.  
 
Conversely, the more intensive HIV care models were the most effective interventions. Home-
based case management interventions, which provided additional counseling to identify and 
address specific barriers which may not be recognized in the clinical setting, showed improved 
adherence and viral suppression outcomes. Individualized care and treatment within a larger 
health system may be the most efficient way to identify multiple or evolving challenges and then 
respond with a custom combination strategy. For example, if an adolescent or youth faces family 
discrimination, inability to miss school for clinic appointments, and lack of a trusted clinician 
relationship, the case-management intervention can target this specific barrier combination – 
family and social isolation, structural challenges of clinic-based care, and poor provider 
relationship (69, 70).   
 
Several methodological limitations in the studies included should be noted. While community 
adolescent treatment supporters significantly improved outcomes (57), ART adherence was 
ascertained through self-report which may be subject to social desirability bias artificially 
leading to a positive effect. More objective adherence measures such as MEMS, drug levels or 
VL outcomes could avoid bias. The community-based support worker intervention also showed 
improved outcomes (56), but assignment to the intervention was not randomized. Patients 
received the intervention based on availability of support workers in the area, thus unmeasured 




more developed or easier-to-access locations. Further, as this intervention was evaluated using 
existing clinical data in a retrospective cohort design, data on the quality and consistency of 
intervention implementation is lacking, including frequency of home visits, type of support 
provided, and content of counseling. Lastly, a majority of studies report results just 1-year from 
implementing the intervention (50, 51, 52, 54, 56). Evaluation of an intervention’s effect over a 
longer period, particularly for new models of HIV care, could provide information on the long-
term durability of an intervention on participant outcomes.  
 
An additional limitation is the inability to identify adolescents and youth who have adequate 
ART adherence but are not virally suppressed, likely because of the presence of ART drug 
resistance. For participants who are ART-naïve or who have changed ART regimens, VL 
outcomes can accurately reflect improved ART adherence, but those who may have acquired 
ART drug resistance are unlikely to be VL suppressed even with improved ART adherence (71). 
Four of the seven studies in this review only report VL outcomes and not an ART adherence 
measurement and only one is limited to ART-naïve participants (56). Reporting the ART 
regimen prescribed could begin to address this limitation since research shows certain regimens 
are more likely to produce resistance than others (72, 73). Only one study in this review included 
data on participants’ prescribed ART regimen (53). 
 
Some interventions implemented in a high income setting improved outcomes among 
adolescents and youth (58-61) and may be feasibly adapted for use in resource-limited settings. 




access to internet and mobile phones among young people in LMICs (74). Conversely, 
implementing interventions involving cognitive behavioral theory and motivational interviewing 
in high-burden resource-limited settings is unlikely due to the high level of counselor training 
(i.e. implemented by PhD-level practitioner) and amount of time required for individualized 
counseling.  
 
Medication-related barriers – side-effects and ease of daily dosing – are critical aspects of 
adherence and require simplification. We did not include studies which address such barriers 
through use of alternative regimens or formulations. Use of more potent and/or better tolerated 
ART regimens such as integrase inhibitors, long-acting and injectable regimens (75-77) have 
shown promise among adults and should be examined among adolescents and youth. Other 
medication-related interventions among adolescents and youth such as weekends off regimens 
have been shown to be non-inferior (78), and single-tablet regimens have achieved significantly 
higher VL suppression rates than multi-tablet regimens (79). Medication-related interventions 
implemented in parallel with health services interventions could significantly and sustainably 
impact adolescent and youth ART adherence.  
 
2.6 Conclusion 
ART adherence and viral suppression outcomes remain a major challenge among adolescents 
and youth living with HIV in LMICs. Recent studies of interventions to improve ART adherence 
among this population show inconsistent effects, highlighting the need for additional, innovative 




targeted interventions have not shown significant effects on adherence, but health services 
interventions which enhance clinic-based care with home-based care, appear promising. There is 
a clear need for appropriately powered studies examining combination interventions. 
Standardizing the key outcomes applied across these studies can streamline limited resources, 
maximize the impact of research, and yield effective interventions to improve health outcomes 
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2.8 Figures and Tables 
Figure 2.1: Flowchart for articles published in PubMed between September 2015 and 
January 2019 which were reviewed under search term [(((((((structural) or ((behavioral))) 
and intervention)) and ((((((ART) or HIV medication) or HAART)) and ((adherence) or 

















Result Level of 
Evidence 
Effective 




N = 332 
Ages: 15-22 
 
Baseline status:  
 In HIV care  
 ART-experienced  
 
Control arm: Standard of care (no text 
messaging) 
1 way arm: Received text messages only 
2-way arm: Received text messages and 
could respond by text message.  
 
Once weekly, for one year, participants in 
the 1-way arm received the message: “we 
hope you are feeling well today”; 
participants in the 2-way arm received 
the same message with the addition: 
“reply 1 if well, 2 if unwell”. Participants 
in the 2-way arm who did not respond or 
responded they were unwell received a 
follow-up message or a call from a study 
coordinator, respectively. 














Mean adherence between 
enrollment and 48 
weeks: 
 
Control arm: 67.0% 
1-way text arm: 64.0% 














 In HIV care  
 ART-experienced  
 
A child savings account matched at a rate 
of 1:1 could be used on medical 
expenses, family business development, 
or education (school lunches and fees) 
was provided to a family. Participants 
also attended 4 workshops on financial 
management, and life skills (e.g. asset 






VL <40 copies/mL 
Viral load Proportion of participants 
with VL <40 copies/mL  
at baseline: 
 
Control arm: 62.2% 
Intervention arm: 55.0% 
(p=0.18) 
 
Proportion of participants 
with VL <40 copies/mL  
at 24 months: 
 
Control arm: 63.4%  
Intervention arm: 65.9%  



















Nasuuna 52  
Uganda 
 




 In HIV care  
 ART-experienced  
 VL >1000 
copies/mL 
Nurses, adherence counselors or expert 
patients administered 3 consecutive 
monthly Intensive Adherence Counseling 
(IAC) sessions to identify barriers and 







Viral load Proportion of participants 
with VL <1000 
copies/mL within 180 
days of completing 3 
IAC sessions: 
 
117/192 (61%) of 
participants received a 
VL test after completing 
3 IAC sessions. Results 
for these 117 include: 
 
Ages 10-14: 34.0% 
(26/77) 
Ages 15-19: 




Health Services Interventions     











 In HIV care  
 ART-experienced   
 ART adherent 
(pill count >95%)  
Participants received multi-month ART 
prescriptions (MMP), which would last 
between 2 and 6 months in order to 
reduce the frequency of required clinic 
visits for ART refills. Start of MMPs 
occurred when participants were deemed 
clinically stable (defined as improving 
CD4 cell count/CD4% or VL 
suppression, or minimal HIV-associated 
morbidity) and ART adherent (defined as 










Viral load Proportion of participants 
with VL <400 copies/mL 




Ages 1-9: 85.0% 
Ages 10-19: 80.0% 
 
60 months: 
Ages 1-9: 85.0% 








Ages: 16-24  
 
Baseline status: 
 In HIV care  
 ART-experienced 
 2 consecutive VL 
<400 copies/mL 
Community-based adherence clubs are 
groups of 25-30 participants who met 
every 2 months for group counseling, a 
symptom screen, and distribution of pre-
packed ART. The groups were supported 
by a community health worker with a 
nurse available for necessary phlebotomy 
(CD4, viral load, creatinine as necessary) 






1) Retained in care 





Viral load Proportion of participants 
retained in care at 12 
months by age: 
 
Ages 16-24: 90.9% 
Ages >25: 94.1% 
(p=0.022) 
 
Among those retained in 
care, proportion of 
participants with VL 
<400 copies/mL at 12 
months by age: 
 
Ages 16-24: 97.2% 


















 Newly diagnosed 
with HIV 
 ART-naïve  
Community-based support workers are 
lay health workers who conducted home 
visits to identify and address participants’ 
challenges with maintaining retention and 
adherence, and offer caregivers education 
and information as necessary. Support 
workers were assigned to a patient at HIV 
testing and stayed through long-term care 
with weekly visits for the first several 
months following ART initiation, then 
monthly for 6 months, then quarterly. 
More frequent visits commenced if clinic 













Pill count and 
viral load 
Participant adherence 
(MPR) at 5 years: 
 
Participants with a 
support worker: 82.5%  
Participants without a 
support worker: 83.0%  
No significant difference 
 
Proportion of participants 
with VL <400 copies/mL 
at 5 years: 
 
Participants with a 
support worker: 81.2%  
Participants without a 











 In HIV care 
 ART-experienced  
Community Adolescent Treatment 
Supporters are adolescents and youth 
ages 18 to 24 living with HIV, trained as 
peer counselors, who made weekly home 
visits to monitor well-being, provide 
adherence counseling and psychosocial 
support, and give caregivers information 
and counseling as necessary. Participants 
were also encouraged to participate in 
monthly support groups at a health 

















Control arm: 48.9% 
Intervention arm: 44.2% 
 
Proportion of participants 
self-reporting adherence 
at 12 months: 
 
Control arm: 39.3%  
Intervention arm: 71.8%  





* If a study included children and/or adults, we report the total number of adolescents and youth included, the age group specified, 









Chapter 3: Point-of-care viral load testing among adolescents and 
youth living with HIV in Haiti: A protocol for a randomized trial to 
evaluate implementation and effect 
 
Chapter 3 has been published as: 
Reif LK, Belizaire ME, Seo G, Rouzier V, Severe P, Joseph JM, Joseph B, Apollon S, Abrams 
EJ, Arpadi S, Elul B, Pape JW, McNairy ML, Fitzgerald DW, Kuhn L. Point-of-care viral load 
testing among adolescents and youth living with HIV in Haiti: A protocol for a randomized trial 
to evaluate implementation and effect. BMJ Open. 2020 Aug 31;10(8):e036147. 
 
3.1 Abstract 
Introduction: Adolescents living with HIV have poor antiretroviral therapy (ART) adherence 
and viral suppression outcomes. Viral load (VL) monitoring could reinforce adherence but 
standard VL testing requires strong laboratory capacity often only available in large central 
laboratories. Thus, coordinated transport of samples and results between the clinic and laboratory 
is required, presenting opportunities for delayed or mis-placed results. Newly-available point-of-
care (POC) VL testing systems return test results the same day and could simplify VL 
monitoring so that adolescents receive test results faster which could strengthen adherence 
counseling and improve ART adherence and viral suppression.  
Methods and analysis: This non-blinded randomized clinical trial is designed to evaluate the 
implementation and effectiveness of POC VL testing compared to standard laboratory-based VL 
testing among adolescents and youth living with HIV in Haiti. A total of 150 participants ages 




arms. Intervention arm participants receive a POC VL test (Cepheid Xpert® HIV-1 Viral Load 
system) with same-day result and immediate ART adherence counseling. Standard care 
participants receive a laboratory-based VL test (Abbott m2000sp/m2000rt) with the result 
available 1 month later, at which time they receive ART adherence counseling. VL testing is 
repeated 6 months later for both arms. The primary objective is to describe the implementation of 
POC VL testing compared to standard laboratory-based VL testing. The secondary objective is to 
evaluate the effect of POC VL testing on VL suppression at 6 months and participant 
comprehension of the correlation between VL and ART adherence.  
Ethics and dissemination: This study is approved by GHESKIO, Weill Cornell Medicine, and 
Columbia University ethics committees. This trial will provide critical data to understand if and 
how POC VL testing may impact adolescent ART adherence and viral suppression. If effective, 
POC VL testing could routinely supplement standard laboratory-based VL testing among high-





Adolescents and youth living with HIV are a vulnerable and underserved population and have 
the poorest treatment outcomes of any age group (1, 2). Since antiretroviral therapy (ART) 
availability has expanded, the number of HIV-related deaths has decreased by 32% in adults 
globally, but increased by 50% in adolescents (3, 4). Adolescence is a period marked by 
physiological and psychological changes as young people navigate biological, emotional, and 
sexual development. Experiences such as establishing identity and independence, managing 
perceived or experienced stigma, and disclosing status to friends or sexual partners, can be 
especially challenging during this period. Without the coping mechanisms which come with 
emotional and social maturity, adolescents are at high risk for inadequate adherence to an ART 
regimen leading to drug resistance, disease progression, and onward transmission of HIV (5, 6).  
 
HIV-1 RNA viral load (VL) is the biomarker which most effectively measures the continued 
effect of ART (7). A suppressed VL, defined as HIV-1 RNA <1000 copies/mL by the World 
Health Organization (WHO), is an informative biomarker indicating that ART is appropriately 
treating the virus, most likely because adherence is adequate (8). Adequate adherence to achieve 
VL suppression is approximately 80% - 90% and median time to VL suppression after 
establishing adequate ART adherence ranges from 1-3 months, depending on the ART regimen 
(9-10).  The WHO recommends VL monitoring (i.e. regular measurement of the quantity of 
HIV-1 RNA in plasma using standard quantitative clinical assays) to evaluate HIV treatment, 
assess treatment failure, and ensure prompt switch to second-line therapy for those on a failing 
regimen. A high VL among a patient with perfect adherence may indicate potential drug 




tool to support viral re-suppression since it provides an opportunity for providers to reinforce 
adherence (14-16). Since adolescents will require treatment for years longer than adults, poor 
adherence, treatment failure, and drug resistance can have more serious consequences making 
VL monitoring particularly important for this population (17, 18).   
 
VL is measured by molecular tests that amplify HIV RNA by polymerase chain reaction (PCR). 
These assays require a high level of technical expertise and laboratory capacity and thus in low 
resource settings have generally been established in central laboratories (19). Thus VL 
monitoring also requires coordinated transportation of specimens and results between clinical 
sites (urban, periurban and rural) and centralized laboratories. Sending samples to a central 
laboratory risks significant delays, misplaced or lost samples and results, and multiple patient 
visits (20-22).  
 
A simplified system, the Cepheid Xpert® HIV-1 Viral Load system, is a point-of-care (POC) VL 
assay that uses individual cartridges which perform an integrated extraction and quantitative real-
time PCR for quantitative measures of HIV RNA (23). The Cepheid Xpert HIV-1 VL system can 
be used at health facilities by minimally-trained staff and results returned to the patient on the 
same day (24, 25). This system gives clinicians the opportunity to identify suboptimal ART 
adherence sooner than standard assays and thus provide real-time feedback to patients about their 
adherence. This may lead to stronger counseling, and allow for quicker clinical decisions about 




and failing treatment, returning VL results faster to reinforce adherence could be an opportunity 
to improve health outcomes.  
 
From a feasibility standpoint, POC VL testing does not rely on the availability of laboratories 
with high technical expertise. Moreover, even when adequate laboratories exist, POC VL testing 
reduces the logistical complexity of transporting specimens and results to and from a clinical 
site. POC VL testing also reduces the amount of time between testing and results. Since results 
are available the same day of testing, this reduces the likelihood of patient attrition prior to 
receiving the result. We hypothesize that the timely return of a concrete, quantitative VL result 
may enhance the impact of adherence counseling, and assist the clinician in formulating a 
suitable treatment plan including regimen changes. From a psychological standpoint, we 
hypothesize that providing a blood sample and receiving the VL result in the same visit could 
help adolescents conceptualize the connection between behavior (ART adherence) and potential 
for negative health outcomes (high VL). As adolescents develop cognitively, they are still 
transitioning from concrete thinking to abstract thinking and they may lack the conceptual 
understanding of long-term or currently unseen consequences of not adhering to a medication 
regimen (26-28).  
 
While the theoretical benefits of POC testing appear promising, drawbacks in their field 
implementation have been highlighted in the literature. POC VL testing requires a constant 




stock, store, and safely dispose of cartridges (29). Evaluating the feasibility of implementing a 
new POC VL testing protocol is needed.  
 
We designed a randomized clinical trial (NCT03288246) to evaluate the implementation of POC 
VL testing and its effect on health outcomes and knowledge compared to standard of care, 
laboratory-based VL testing, among adolescents and youth living with HIV. The primary 
objective of the study is to describe the implementation of POC VL testing compared to standard 
laboratory-based VL testing. We hypothesize that POC VL testing paired with same-day patient 
education and counseling will result in a higher proportion of participants receiving their test 
result (fewer samples lost or results not accurately linked back to charts), and shorter time 
between testing and participant receipt of results. The secondary objective of the study is to 
evaluate the effect of POC VL testing on VL suppression and participant comprehension of the 
correlation between ART adherence and VL suppression. We hypothesize that providing same-
day VL test results accompanied by adherence counseling the same day as testing could improve 
these outcomes.   
 
3.3 Methods and Analysis  
Study Design  
This study is designed as an un-blinded randomized clinical trial among adolescents and youth 
ages 10-24 years living with HIV who have been on ART for >6 months. Adolescents are 
randomized 1:1 to one of two arms: 1) the point-of-care arm (POC) or 2) the standard of care 




informed by the VL result the same day as testing. In the SOC arm, adolescents have a standard 
laboratory-based test and then approximately 1 month later, once the VL test result is processed 
at the central laboratory and the result is linked back to the electronic medical record (EMR), 
they receive adherence counseling informed by the VL result at the follow-up clinic visit. The 
steps between sample collection and participant receipt of VL results, comparing the POC and 
SOC arms are described in Figures 3.1a and 3.1b. A randomized design allows us to rigorously 
evaluate the implementation of POC VL testing compared to standard laboratory-based VL 
testing comparing the steps involved with processing the VL test in each system. The 
randomized design will also minimize potential bias due to confounding factors in evaluation of 
the impact of POC VL testing on VL suppression and comprehension of the correlation between 
VL and ART adherence.   
 
Study Site 
The study takes place at GHESKIO, the French acronym for the Haitian Group for the Study of 
Kaposi's Sarcoma and Opportunistic Infections, an HIV/AIDS clinic in Port-au-Prince, Haiti. 
GHESKIO is the largest provider of HIV care in the Caribbean and provides HIV counseling and 
testing to nearly 40,000 patients and ART to 20,000 patients annually. GHESKIO has an on-site 








Intervention arm: Point-of-care VL testing 
The intervention arm participants are asked to arrive for their visit before 11am. They receive the 
Cepheid GeneXpert HIV-1 POC VL test. The blood sample is collected onsite at the phlebotomy 
clinic and processed onsite by a laboratory technician. Processing includes centrifuging the blood 
sample for 15 minutes to separate plasma from whole blood, and then the Cepheid GeneXpert 
HIV-1 VL system automates the testing processes including RNA extraction, purification, 
reverse transcriptions, and cDNA real-time quantification in one cartridge within 90 minutes. We 
chose the Cepheid GeneXpert HIV-1 VL testing system because minimally-trained, onsite staff 
can test samples individually and on-demand (25, 30). The assay is WHO prequalified for use in 
HIV management with plasma (31) and in an evaluation to determine its performance relative to 
the laboratory-based Abbott m2000sp/m2000rt assay, with a similar threshold of detection (40 
copies/mL), was highly concordant (23).  
 
The POC VL test result is processed and returned to the study nurse within 3 hours of collecting 
the blood sample, which the study nurse then provides to the participant with immediate 
adherence counseling. In the event that the test result is not available the same day (e.g. there is 
an error with the POC VL assay or the participant arrives at the clinic too late for the test to be 
processed the same day), the clinician receives the result from the onsite laboratory the next day 
and the participant is called to return for the result. Participants are followed monthly and receive 





Control arm: Standard laboratory-based VL testing 
In the current standard of care, participants receive a standard laboratory-based VL test which 
requires samples to be sent offsite to a central laboratory for processing (~1 hr drive from the 
clinic). At the central laboratory, they are stored, batched with other samples, and run weekly in 
the fully automated Abbott m2000sp/m2000rt system. Once the result is available, it is manually 
entered by laboratory staff into an excel spreadsheet which is emailed to the clinic and then 
manually entered by data management staff into the electronic medical record (EMR). At the 
next visit, if results are available, the clinician retrieves them from the EMR to return to the 
patient and provide appropriate adherence counseling informed by the result. The duration of this 
process – from sample collection to patient return of results – varies depending on the volume of 
samples collected each day and on laboratory and data management staffing. Average time from 
blood collection to availability of the result in the EMR is 2-3 weeks. Per standard clinical care, 
adolescents receive the VL result and adherence counseling informed by the result at their next 
visit, 1 month after providing the blood sample. There is no mechanism for ‘flagging’ a high VL 
to alert a clinician and subsequently the participant. We have made as little modification to this 
standard protocol as possible. Participants are followed monthly and SOC arm participants 
receive adherence counseling informed by the VL test result if it is available in the EMR at the 
next monthly visit.  
 
Participants in both arms receive a reminder phone call one week before a visit; on this call the 
POC arm participants are reminded to arrive before 11am for a visit with a VL test scheduled. 
Participants in both arms receive the same adherence counseling curriculum and messages 




test result. For example, if a participant’s VL is <1,000 copies/mL, counseling includes positive 
feedback for ongoing ART adherence and a discussion on how to prepare for or prevent any 
potential challenges to maintain this. If a participant’s VL result is >1,000 copies/mL, counseling 
includes identifying current barriers to ART adherence and plans for how to address these in 
order to improve adherence and they are scheduled for a repeat VL test 3 months from the initial 
VL test. A key difference between arms is the timing of the adherence counseling – intervention 
arm participants receive this the same day as testing (i.e. month 1 and month 6), and standard of 
care arm participants receive this 1 month after testing (i.e. month 2 and month 7).  
 
Study Objectives, Outcomes, and Measurements 
The primary study objective is to describe the implementation of VL testing across study arms, 
including the proportion of participants who receive a VL result and the timeliness of the result 
(Table 3.1). Process steps include: 1) generating a valid VL test result, 2) returning the VL test 
results to the participant, and 3) providing adherence counseling informed by the VL result. We 
will describe the proportion of steps achieved, the time between each step, and document reasons 
for any delays or failures to reach a step, comparing study arms. The primary outcome will 
compare the proportion of participants in each arm who receive their VL test result within 6 
weeks of VL testing. This allows for a short time buffer for SOC arm participants if 
appointments are not scheduled exactly 1 month from the previous visit for reasons related to 





The secondary study objective is to evaluate the effect of POC VL testing on health outcomes 
and participant knowledge including: 1) VL suppression at 6 months and 2) comprehension of 
the correlation between VL and ART adherence (Table 3.1). VL suppression at 6 months is 
defined as a HIV-1 RNA VL <1,000 copies/mL using results from the laboratory-based Abbott 
VL test for both arms. Demonstrated comprehension, by the adolescent, of the correlation 
between ART adherence and VL is assessed using a VL knowledge questionnaire which was 
adapted from studies that assessed general HIV/AIDS knowledge (33-35).  This questionnaire is 
similar to questions used to assess a cognitive behavioral program – the “Life-steps Program” – 
to improve drug adherence and HIV knowledge among adolescents and youth (28, 36). 
Comprehension is measured as a binary outcome – participants who answer >60% of questions 
correctly on the VL knowledge questionnaire are defined as having demonstrated 
comprehension. 
 
ART adherence will also be measured at 1, 4, and 6 months by self-report and assessed using a 
modified version of the AIDS Clinical Trials Group (ACTG) questionnaire to evaluate adherence 
by 7-day recall, which has been shown to be more accurate for adolescents and youth than 30-
day recall assessments (37-41). Self-reported adherence is measured as a binary variable: “sub-
optimal” and “optimal” based on the answer to the question: “In the last 7 days, on how many 
days did you miss at least one dose of any of your ART medicines”? A response of 1 or more 





At each visit with a VL test, participants also provide a dried blood spot sample of whole blood. 
Samples from a subset of 50 participants (the first 25 enrolled in each arm) will be analyzed to 
measure the cumulative level of tenofovir-diphosphate (TDF-DP) drug level in the blood using 
liquid chromatography-tandem mass spectrometry (42). This will provide an additional marker 
of ART adherence. It will also allow us to assess the correlation between cumulative TDF-DP 
drug concentration, VL, and self-reported adherence to determine if an unsuppressed VL is a 
result of an ineffective drug regimen or poor adherence.  
 
Study Population: Eligibility and Enrollment 
All adolescents who had a VL test >6 months prior are screened for invitation to the study. 
Specific inclusion criteria include adolescents and youth living with HIV ages 10-24 who have 
been on ART >6 months as documented in the GHESKIO EMR; permanent residence in Port-au-
Prince, and able to provide informed consent/assent. Exclusion criteria include participants who 
are pregnant at enrollment; co-infected with tuberculosis or other co-morbidities including 
cognitive impairment, bipolar disorder, psychosis; are in current need of inpatient psychiatric 
hospitalization; or require an urgent VL test or an ART regimen change the day of enrollment. 
All participants are followed at GHESKIO for the duration of the study. 
 
Eligible adolescents are referred to research staff who provide an overview of the study, evaluate 
participant understanding of the study, and complete study enrollment for interested participants. 
Adolescents and youth 18 years and older provide written consent and adolescents younger than 




Study Activities and Data Collection 
Participants are randomized (1:1) using a computer randomization software to either the POC 
arm or the SOC arm at enrollment and followed monthly, per standard clinical protocol. Study-
scheduled VL tests are conducted at month 1 and month 6. Participants with a VL >1,000 
copies/mL at month 1 have a repeat VL test done at month 4 with adherence counseling. This 
adheres to standard clinical care – patients with a VL >1,000 copies/mL receive counseling to 
improve adherence and are scheduled for a repeat VL test 3 months later (Figure 3.2).  
 
All participants complete a baseline questionnaire at study enrollment which captures socio-
demographic data and clinical history. All participants complete the VL knowledge questionnaire 
at baseline and 1 month after receiving VL results and adherence counseling, to evaluate change 
in knowledge after receiving VL results and adherence counseling. All participants in the POC 
arm complete a questionnaire evaluating their experience with POC VL testing to determine if 
they would accept POC VL testing as standard care. All participants complete an adherence 
assessment at month 1, 4, and 6. The timing of study activities including all questionnaires are 
listed in Table 3.2. Data quality control and assurance are conducted regularly for entry errors. 
Standard data collection, assessment, and reporting for any adverse events are also conducted.  
 
Sample Size and Power Calculations 
We calculated the required sample size to address the primary outcome of the study: the 
proportion of adolescents who receive a VL result within 6 weeks of the month 1 VL test. We 




and interviews with providers at GHESKIO and hypothesize the primary outcome will be 
common. Between July 2016 and December 2016, we observed that 50% of participants’ VL 
results were entered into the EMR within 6 weeks of sample collection and confirmed this with 
providers in the clinic. The method we have chosen for calculation of the sample size is a simple 
comparison of proportions. We assume two-tailed tests, set a significance level at 5% and power 
of 80%. For the primary outcome, with a sample size of 124 (62 per arm) we will have 80% 
power to detect a 20% increase (on the additive scale) in the proportion of patients who receive 
their VL result within 6 weeks of the month 1 VL test (i.e. 70% in the SOC arm vs. 90% in the 
POC arm). 
 
We also calculated the required sample size to address a secondary outcome of the study: the 
proportion of adolescents who achieve a VL <1000 copies/mL at 6 months. We anticipate the 
secondary outcome will be slightly less common. A cross-sectional retrospective analysis of VL 
results among adolescents ages 10-24 who had been on ART >6 months at the GHESKIO 
adolescent HIV clinic in 2016 showed 40% were virally suppressed. For the secondary outcome, 
with the same sample size of 124 (62 per arm) we will have 80% power to detect a 25% increase 
in the proportion of participants who are virally suppressed at 6 months from the index VL test 
(i.e. 40% in the SOC arm vs. 65% in the POC arm). Assuming we will achieve 85% follow-up in 







Analysis and Statistical Methods 
We will conduct an ‘intent to treat’ analysis comparing participant outcomes by randomized 
study arm. We will compare the baseline characteristics between arms to determine if our 
randomization process achieved a balance of these characteristics (e.g. age, gender, presumed 
route of HIV transmission, age at ART initiation, time on ART, current ART regimen, baseline 
ART adherence, and baseline VL). For the primary outcome, we will compare the proportion of 
participants who receive the month 1 VL test result within 6 weeks of testing, by randomization 
arm. For the secondary outcomes, we will compare the proportion of participants who achieve or 
sustain a VL <1000 copies/mL 6 months from the month 1 VL test, by randomization arm. We 
will conduct secondary analyses to examine predictors of all outcomes (e.g. time on ART, 
presumed route of HIV transmission) and assess whether there are subgroups among which these 
outcomes are more commonly achieved. For all outcomes, we will conduct statistical 
comparisons using Chi-square tests for categorical variables, and t-tests for bell-shape-
distributed continuous variables. All p-values will be 2-tailed. All analyses will be performed 
using R 3.6.3. 
 
Patient and Public Involvement  
The GHESKIO Community Advisory Board (CAB) facilitates communication between the 
GHESKIO clinic and Haitian communities. The CAB includes adolescent members who are 
specifically involved in discussions on projects involving adolescents and youth. The study was 




provided feedback on the design and implementation. At the end of the study, the CAB will 
comment on the findings and will contribute to the dissemination plan. 
 
3.4 Discussion 
Adolescents and youth living with HIV are a particularly vulnerable population and central to the 
global HIV epidemic. Early and prolonged virologic suppression is associated with better clinical 
and neurocognitive outcomes among children and adolescents living with HIV (43, 44). We 
hypothesize that POC VL testing, with same-day return of results, will lead to earlier 
identification of patients with poor adherence, earlier opportunities to intervene, and ultimately 
earlier achievement of sustained ART adherence and viral suppression. If shown to be feasible 
and clinically effective, POC VL testing could be scaled up to routinely supplement standard 
laboratory-based VL testing for use among high-risk populations such as adolescents.  
 
While the theoretical benefits of POC technologies appear substantial, drawbacks in their field 
implementation have been highlighted in the literature (29, 45-50). Simple ‘scale-up’ of POC 
testing has to take into consideration the larger health system and the subsequent changes that 
POC testing introduces. These changes include shifts in the supply chain which require clinics to 
monitor stock of different and potentially more complex supplies as well as securing a constant 
power supply and extra storage space. While designed to simplify processes, POC testing 
increases clinic responsibility and requires additional capacity (48, 49). POC testing also places 
additional responsibility on the provider and a longer visit is perceived negatively by those 




experience including longer visits. For example, one study has shown that some patients still 
choose to return for their test results at a later visit if POC testing lengthens the visit (e.g. waiting 
1 hour for result) (51). If POC technologies are not implemented with consideration for the larger 
health system and potential unintended consequences, poor uptake can limit their feasibility and 
impact. In this trial we will evaluate the implementation of POC VL testing to determine if any 
of these potential drawbacks will impact this new protocol and to what extent.  
 
Our trial has several limitations to note. We have a relatively small sample size and the study is 
being conducted at a single site, which could limit the generalizability of our results to other 
locations and among other populations. However, GHESKIO is the largest HIV/AIDS clinic in 
the Caribbean, and the findings of this trial could be used to design and implement similar 
studies to evaluate the impact of a POC VL testing intervention in other settings. Secondly, the 
POC VL testing intervention is narrow in scope when considering the magnitude of barriers that 
impede adequate ART adherence among adolescents. We recognize it is optimistic that returning 
a VL test result the same day can make widespread impact to improve ART adherence and viral 
suppression. If POC VL testing is shown to be effective, it could be used in combination with a 
package of additional interventions which address other patient-level barriers like stigma or lack 
of social support. We also acknowledge that there are potential unintended consequences to 
returning test results the same day – adolescents may feel ‘caught’ or shamed if the test result 
does not align with their reported self-adherence (52). However, counselors are comprehensively 
trained to never convey blame or shame to the adolescent, but rather to show acceptance that 





Adolescent and youth HIV outcomes remain far from the UNAIDS 90-90-90 targets and 
innovative interventions are needed to both decrease morbidity and mortality among this 
vulnerable population and curb onward transmission of HIV. This trial will provide evidence as 
to whether a POC VL test is feasible and can simplify the VL testing process, and importantly 
whether it will result in faster clinical decision-making and improved health outcomes for 
adolescents with HIV (53, 54).  
 
Ethics and dissemination  
This study is approved by the GHESKIO, Weill Cornell Medicine, and Columbia University 
ethics committees. All participants sign an informed consent form, and assent form as indicated, 
prior to any involvement in the study. The trial began enrollment in May 2018 and completed in 
August 2019. The study results will be presented at international scientific conference and will 
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3.6 Figures and Tables 
Figure 3.1a: Standard Laboratory-based VL Testing Steps 
 




Table 3.1: Study Objectives, Outcomes, and Measurements 
Objective 1: Describe the implementation of POC VL testing compared to standard 
laboratory-based testing.  
Outcome Measurement 
Description of VL testing steps Proportion of participants with: 
1) a valid VL test result generated 
2) a VL test result returned  
3) adherence counseling informed by the VL result received 
Receipt of VL test result  Receive of VL test result within 6 weeks  
  
Objective 2: Measure the effect of POC VL testing on health outcomes. 
Outcome Measurement 
ART adherence No reported missed doses by self-report
a
 
VL suppression < 1000 copies/ mL 
Comprehension of the 
correlation between ART 
adherence and VL result 






Assessed using a modified version of the AIDS Clinical Trials Group (ACTG) questionnaire 
for 7-day recall 
b 






Figure 3.2:  Study Schema 
Informed Consent/Assent and 
Randomization (N=150) 
Month 6: Outcome measurements for 
ART Adherence and VL suppression 
Standard of Care Arm (N=75) 
VL Test (Abbot) at Month 1, 4*, and 6 and the 
result returned with adherence counseling one 
month later. 
Point of Care Arm (N=75) 
 VL Test (Xpert) at Month 1, 4*, and 6 with the 
result returned with adherence counseling the same 
day as testing. 
Adolescents and youth ages 10-24 
years living with HIV and on ART 
>6 months 
Monthly follow-up Monthly follow-up 
* Month 4 VL test administered only to those with a VL > 1000 copies/µl at Month 1 
Month 6: Outcome measurements for 






Table 3.2: Schedule of Study Activities and Follow-up 
  Enrollment Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 
POC Arm   
Consent/Randomization X               
Baseline questionnaire X               
Adherence assessment   X     X   X   
VL knowledge questionnaire X   X           
Acceptability questionnaire     X           
VL test (Xpert)   X     X*       
VL test (Abbott)   X      X    X   
DBS Collection   X     X   X   
Adherence counseling informed 
by VL result 
  X     X*   X   
SOC Arm   
Consent/Randomization X               
Baseline questionnaire X               
Adherence assessment   X     X   X   
VL knowledge questionnaire X     X         
VL test (Abbott)   X     X*   X   
DBS Collection   X     X   X   
Adherence counseling informed 
by VL result 
    X     X*   X 
 




Chapter 4: Point-of-care Viral Load Testing Among Adolescents 
and Young Adults Living with HIV in Haiti: A Randomized Control 
Trial 
 
Chapter 4 is in preparation for submission: 
Reif LK, Belizaire ME, Seo G, Rouzier V, Severe P, Joseph JM, Joseph B, Apollon S, Abrams 
EJ, Arpadi S, Elul B, Pape JW, McNairy ML, Fitzgerald DW, Kuhn L. Point-of-care viral load 
testing among adolescents and young adults living with HIV in Haiti: A randomized control trial.  
 
 
4.1 Abstract  
Background: HIV viral load (VL) monitoring is an opportunity to reinforce antiretroviral 
therapy (ART) adherence. Standard VL testing requires high laboratory capacity and coordinated 
transfer of samples and results between clinic and laboratory which can result in delayed or mis-
placed results. We evaluated whether point-of-care (POC) VL testing returned results faster and 
lead to improved outcomes.     
Methods: We conducted an unblinded randomized trial comparing POC VL testing to standard 
VL testing among 150 adolescents and young adults, ages 10-24 years, living with HIV in Haiti. 
Participants were randomized 1:1 to the POC arm for a POC VL test with same-day result and 
adherence counseling or standard care (SOC) arm for a laboratory-based VL test with result and 
adherence counseling given 1 month later. Both arms received a VL test 6 months later. The 
primary objective was to compare the efficiency of VL testing between arms; secondary 




Results: Participants were ages 12-24 years, on ART for an average of 6 years, and 57% had a 
VL <1,000 copies/mL at baseline. Participants in the POC arm were more likely to receive their 
VL test result within 6 weeks of blood collection than participants in the SOC arm (94.7% vs. 
80.1%; p<0.01). ART adherence as measured by self-report appeared worse in the POC arm, but 
ART adherence measured by drug level indicated no difference between arms. An unanticipated 
finding was that the association between VL >1000 copies/mL and low self-reported ART 
adherence were stronger in the POC arm (OR: 6.57; 95%CI: 2.12-25.21) than the SOC arm (OR: 
2.62; 95%CI: 0.97-7.44) suggesting more accurate self-reporting of adherence in the POC arm. 
Viral suppression at month 6 did not differ by arm (POC: 58.7% vs. SOC: 57.3%; p=0.87). 
Conclusion: POC VL testing was effectively implemented in this low-resource setting and 
provided faster VL test results. POC testing was also associated with greater accuracy in ART 
adherence reporting. POC VL testing is a pragmatic intervention that may enable clinicians to 
identify and provide real-time counseling for those with high VL to provide enhanced counseling 






4.2 Introduction  
Globally 4 million adolescents and young adults (AYA) ages 15-24 are living with HIV (1). 
Access to antiretroviral therapy (ART) has made it increasingly possible to provide life-saving 
HIV treatment in this vulnerable population. The goal of ART is to achieve viral suppression to 
re-establish immunological function, prevent further morbidity and mortality, and curb further 
HIV transmission. However, AYA have poorer ART adherence than all other age groups and are 
twice as likely to have an unsuppressed viral load (VL) (2-4).  
 
The World Health Organization (WHO) recommends HIV VL monitoring to regularly assess the 
effectiveness of ART (5). A high VL can indicate inadequate ART adherence or potential drug 
resistance and requires prompt enhanced adherence counseling or a change in ART regimen for 
those on a failing regimen (6, 7). Given AYA are at higher risk for unsuppressed VL and will 
require ART for years longer than adults, identifying poor adherence, and preventing treatment 
failure with VL monitoring is important for this age group.  
 
Standard laboratory-based HIV VL testing requires a high level of technical expertise and 
laboratory capacity which are commonly only established in large, central laboratories and not 
available on-site at clinics. Thus, coordinated transfer of specimens and results between the 
clinic and off-site laboratory is necessary which involves multiple patient visits for testing and 
receipt of results, and risks significant delays and/or misplaced or lost samples and results. On-
site, point-of-care (POC) HIV VL testing reduces the logistical complexity of transporting 




Returning and discussing VL results can reinforce ART adherence and support viral re-
suppression (8-10), thus a POC VL test with timely return of the result could enhance the impact 
of adherence counseling and lead to improved outcomes. Quicker VL test results could enable 
clinicians to provide real-time feedback about adherence and make clinical decisions about 
appropriate treatment sooner. 
 
We conducted a randomized trial to evaluate whether POC VL testing, as compared to standard 
VL testing, could more efficiently return test results, and affect outcomes including ART 





This study was conducted at GHESKIO, the French acronym for the Haitian Group for the Study 
of Kaposi’s Sarcoma and Opportunistic Infections, an HIV/AIDS clinic in Port-au-Prince, Haiti. 
GHESKIO provides HIV care to over 700 AYA living with HIV and on ART. GHESKIO has an 
on-site satellite laboratory which performs rapid HIV testing and a large centralized laboratory 
approximately 1 hour drive from its primary patient clinic where all other HIV, CD4, and VL 







We conducted an unblinded randomized control trial to test the hypothesis that POC VL testing 
will return VL test results sooner and improve outcomes, compared to standard laboratory-based 
VL testing (NCT03288246). Details of the research protocol have been previously published 
(11). The randomized design was chosen to evaluate a tightly-defined health services 
intervention and limit bias from confounders. The trial was conducted in a resource-limited 
setting to enhance potential reproducibility of findings in similar settings. Individual participants 
were randomized 1:1 to either the point-of-care (POC) or standard of care (SOC) arms using a 
randomization software program. In the POC arm, VL tests were completed on-site and results 
returned with adherence counseling the same day. In the SOC arm, VL tests were completed 
according to standard care by transporting blood samples to the central laboratory and results 
returned with adherence counseling at a clinic visit one month later. Participants in both arms 
received the same WHO-recommended adherence counseling guided by the VL test result (12, 
13). The key difference between arms was the timing of adherence counseling – the same day as 
testing for the POC arm vs. one month later for the SOC arm. The protocol was approved by the 
ethics committees at Weill Cornell Medicine, GHESKIO, and Columbia University.  
 
Study Population  
Eligibility criteria were age 10-24 years, aware of HIV status, on ART >6 months, with 
permanent residence in Port-au-Prince. Exclusion criteria were pregnancy, tuberculosis co-




years provided written consent and <18 years provided written assent with written parental or 
guardian consent. 
 
POC Arm  
All VL tests for participants in the POC arm were performed on the Cepheid GeneXpert system 
using Xpert HIV-1 Viral LoadTM cartridges (Cepheid, Sunnyvale, CA). A GeneXpert 4- module 
instrument was placed at the on-site laboratory and operated by laboratory technicians. This 
system uses individual cartridges which perform integrated extraction and quantitative real-time 
PCR for measurement of HIV-1 RNA. Processing the assay includes centrifuging the blood 
sample for 15 minutes to separate plasma, and then 90 minutes of run-time in the instrument. 
Participants were asked to arrive before 11am to allow time for same-day processing. When VL 
test results were ready, the laboratory technician alerted the study nurse by phone for pick-up and 
the study nurse provided the result coupled with adherence counseling to the participant. If the 
result was not available the same-day, the participant returned for the result and adherence 
counseling as soon as available.  
 
SOC Arm 
All VL tests for participants in the SOC arm were transported to the central laboratory, and 
processed in weekly batches in a fully automated Abbott m2000sp/m200rt system (Abbott, Des 
Plaines, IL). Once available, results were manually entered by laboratory staff into an excel 
spreadsheet, emailed to the clinic, and manually entered by data management staff into the 




the EMR to return to the participant with adherence counseling. The timing of this process 
depended on the volume of samples to process, and laboratory and data management staffing.   
 
Study Procedures 
VL testing was done at month 1 and at month 6 in both arms. Following Haitian national 
guidelines, those with a VL >1,000 copies/mL at month 1 had a repeat VL test at month 4. A 
questionnaire capturing sociodemographic and clinical history data was administrated at study 
enrollment. A VL knowledge questionnaire was administered at enrollment and 1 month after 
receiving VL results. Adherence assessments were administered at months 1, 4, and 6 
(Supplementary Table 4.1).  
 
Dried blood spots (DBS) collected from the first 62 participants enrolled (31 in each arm) who 
were receiving tenofovir in their ART regimen at the 6 month time point were tested for 
tenofovir-diphosphate (TDF-DP). TDF-DP drug level was measured using liquid 
chromatography-tandem mass spectrometry at the Colorado Antiviral Pharmacology Laboratory 
at the University of Colorado (14).  
 
Objectives, Outcomes and Measurements 
The primary objective was to evaluate the adequacy of implementation of POC VL testing 
compared to standard laboratory-based VL testing. Completion of each VL testing step was 




proportion of participants in each arm to receive the VL test result within 6 weeks of sample 
collection. A 6-week window was allowed to take into account scheduling around school, work, 
or holidays. Reasons for failure to achieve any step and the duration of time between each step 
were ascertained.  
 
Secondary objectives were to evaluate the effect on ART adherence, VL, and participant 
understanding of the relationship between ART adherence and VL at month 6. Self-reported 
ART adherence was measured using a modified AIDS Clinical Trials Group (ACTG) 
questionnaire (15-17). Three questions assessed self-reported adherence over the preceding 7 
days: (1) the number of missed doses; (2) a scale rating of how good a job the participant did 
taking ART as prescribed; and (3) a scale rating of how often the participant took ART as 
prescribed. Optimal adherence was defined as a response of <2 doses, “very good”, and “always” 
on questions 1, 2 and 3, respectively. Responses were recoded with equal weighting to create a 
standardized score out of 100 with 100 representing the best possible adherence. A composite 3-
question score was created with equal weighting for the standardized score on each question.   
 
ART adherence was also measured by TDF-DP drug level (f/mol per DBS), reported as mean 
and standard deviation (SD), and interpreted as the number of doses per week, categorized as: <2 





VL tests in both arms were processed with the standard laboratory-based VL assay (Abbott) and 
these data used for the VL endpoints. The Cepheid Xpert assay and Abbott assay have the same 
threshold of detection (40 copies/mL) and are highly concordant (18, 19).  
 
Participants’ understanding of the relationship between VL and ART adherence was measured 
using a questionnaire adapted from those that assess general HIV/AIDS knowledge (20-22). 
Understanding of this relationship was defined as answering 3/5 (60%) questions correctly on the 
VL knowledge questionnaire administered one month after receiving the VL result and ART 
adherence counseling.   
 
Sample Size 
The study was powered to detect a 20% increase in the proportion of participants who received a 
VL result within 6 weeks of sample collection (i.e. primary outcome) and a 25% increase in the 
proportion of participants with a VL <1,000 copies/mL (i.e. secondary outcome). A sample size 
of 124 (62 per arm) was chosen assuming 70% of participants would receive the VL test result 
within 6 weeks of sample collection in the SOC arm versus 90% in the POC arm, and 40% 
would have a VL <1,000 copies/mL at month 6  in the SOC arm versus 65% in the POC arm. 








The analysis was intent-to-treat comparing outcomes by arm of all 150 participants enrolled. 
Statistical comparisons of outcomes between arms used Chi-square tests for categorical 
variables, and t-tests for normally distributed continuous variables. McNemar tests were used to 
determine statistical difference between participants’ baseline and follow-up results. Logistic 
regression was used to examine associations between variables. All p-values are 2-tailed. All 
analyses were performed using R 3.6.3.   
 
4.4 Results 
Between May 3, 2018 and April 16, 2019, a total of 160 participants were screened for eligibility 
and 150 were enrolled and randomized (Figure 4.1). Participant median age was 20 years (IQR 
18-22), 60% were male, and 70% had acquired HIV perinatally. The average age at ART 
initiation was 13 years with an average time on ART of 6 years. At ART initiation, a large 
majority of participants were prescribed an NRTI+NNRTI regimen, according to national 
guidelines. By the time of study enrollment, 45% had been switched to an NRTI+PI regimen or 
an NRTI+INSTI regimen. At study enrollment, 57% of participants had a VL <1,000 copies/mL. 
Sociodemographic and clinical measurements were similar between arms at enrollment (Table 







Implementation Outcomes   
Participants in the POC arm were more likely to receive the VL test result within 6 weeks of 
blood collection than participants in the SOC arm (94.7% vs. 80.1%; p<0.01) (Table 4.2). In the 
POC arm, median time between blood collection and participant receipt of results, for those who 
received a result the same day, was 2.7 hours (IQR: 2.5-3.2; range: 1.7-6.0). A total of 81.8% 
(148/181) of POC VL tests processed were returned the same day. When a POC VL test result 
was not returned the same day (33/181; 18.2%), the median time to receipt of result was 7 days 
(IQR 6-20; range: 1-36). In contrast, in the SOC arm, the median time between blood collection 
and availability of the result in the EMR was 8 days (IQR: 6-13; range: 5-39), and median time 
to participant receipt of the result was 30 days (IQR: 28-35; range: 19-126).  
 
The most common reason a POC VL test result was not returned the same day was that the clinic 
closed before assay processing completed (21/33; 63.6%). In 71.4% (15/21) of these instances, 
the participant arrived at the clinic after 11am. Other reasons included: the participant opted not 
to wait for the assay to be processed (8/33; 24.2%) or there was a stock-out of the cartridges the 
day of the VL test (4/33; 12.1%). When the result was not returned the same day, 90.9% (30/33) 
were still returned within 6 weeks. In total, of all the VL tests completed in the POC arm, only 
1.7% (3/181) of results were not returned the same day and the participant did not return to 
receive the result within 6 weeks.  
 
In the SOC arm, when a VL result was not returned within 6 weeks, the primary reason was the 




(76.9%; 20/26). For the remaining 23.1% (6/26), the participant attended the visit but the result 
was unavailable because of a delay in either performing the assay at the central laboratory or 
relaying the result to the clinic. 
 
The total amount of time spent in the clinic for VL testing and receipt of results was similar 
between the two arms despite the extra time for processing the POC VL test. In the POC arm, 
when blood collection, return of the VL test result, and adherence counseling were all completed 
in one visit, the visit lasted a median of 4.1 hours (IQR 3.6-4.7; range 2.7-5.8). In the SOC arm, 
two visits were required – one for blood collection and one for returning the VL result and 
adherence counseling. The visit for blood collection lasted a median of 1.9 hours (IQR 1.8-2.3; 
range 1.0-3.4) and the visit for returning the VL result and adherence counseling lasted a median 
of 1.9 hours (IQR 1.5-2.2; range 1.2-2.9). Combined, the two visits lasted a median of 3.9 hours 
(IQR 3.3-4.4, range 2.5-5.2).  
 
Over the course of the study, 10 participants were observed to have treatment failure, defined as 
two consecutive VL measurements >1000 copies/mL, 6 (8.0%) in the POC arm and 4 (5.3%) in 
the SOC arm. All were switched to a second line regimen. In the POC arm, 5 switched the day of 
the blood draw, and 1, who chose not to wait for the VL result, was switched at the next visit 29 
days later. In the SOC arm, all 4 were switched at the next monthly visit, with a median time 






ART Adherence Outcomes   
Self-reported ART adherence was assessed before each VL test in both arms and TDF-DP drug 
levels were measured as a biomarker to compare with self-report. Self-reported adherence 
appeared to be worse in the POC arm than the SOC arm (mean adherence score 76.5 (SD 26.6) 
vs. 87.1 (SD 18.7), p<0.01) (Table 4.3) However, TDF-DP drug levels were close to identical 
between the two arms, suggesting no difference in ART adherence between arms. The mean 
TDF-DP fmol/punch was 993 in the POC arm and 866 in the SOC arm (p=0.56) (Table 4.4b) An 
unanticipated finding that explains this discrepancy is that self-reported ART adherence at month 
6 was more strongly related to VL in the POC arm than in the SOC arm, indicating more 
accurate adherence reporting in the POC arm. In the POC arm, participants who reported sub-
optimal adherence on any of the 3 questions were significantly more likely to have a VL >1,000 
copies/mL (OR: 6.6; 95% CI: 2.1-25.2), whereas in the SOC arm, the association was weaker 
(OR: 2.6; 95% CI: 0.9-7.4) (Figure 4.2). TDF-DP drug levels were also more strongly related to 
self-reported ART adherence in the POC arm versus the SOC arm, further evidence of the 
increased accuracy of self-reported ART adherence in the POC arm (Supplementary Table 2b). 
 
Viral Load Outcomes 
There were no differences in VL outcomes at month 6 in intent-to-treat analyses, if restricted to 
those with 6 month data, or in sensitivity analyses considering those lost to follow-up as failures 
(Table 4.4a). Similar proportions in both arms changed VL status between months 1 and 6: 




month 1 vs. 13.3% (10/75) in the SOC arm; 12.0% (9/75) in the POC arm experienced viral 
rebound vs. 14.7% (11/75) in the SOC arm (p=0.87).   
 
Risk factors for worse VL outcomes were younger age, longer time on treatment, and perinatal 
infection (relative to behavioral infection). In multivariable analysis, only perinatal infection was 
associated with worse VL after adjusting for age and duration of treatment. Participants who had 
acquired HIV perinatally were more likely to have a VL >1,000 copies/mL (OR: 1.8; 95% CI: 
0.9-4.0; p=0.11) than those who acquired HIV behaviorally (Supplementary Table 3). Self-
reported ART adherence and TDF-DP drug levels were similarly lower in perinatally-infected 
participants than in behaviorally-infected participants (Supplementary Table 4.4).  
 
There was no difference between arms in understanding of the relationship between ART 
adherence and VL, though both arms improved in knowledge between baseline and follow-up 
(Supplemental Table 4.5).  
 
4.5 Discussion 
POC VL testing was effectively integrated into a low-resource clinical setting and a majority of 
participants received test results the same day. POC VL testing also appeared to lead to more 
accurate self-reported ART adherence. This may enable clinicians to identify AYA with poor 
ART adherence and high VL and provide counseling or regimen changes sooner, preventing or 




Onsite POC VL testing reduced inefficiencies in the VL testing process. Even in limited 
instances when the result was not available the same day, multiple process steps were eliminated 
(e.g. transporting, batching, and data entry) and clinicians could access the result, identify a high 
VL, and schedule a visit within days. Enhanced adherence counseling, recommended by the 
WHO before an ART regimen change, is an important step in VL monitoring (7, 12, 23). Studies 
in low-resource settings have shown the time between identifying a high VL and beginning 
enhanced adherence counseling can range between 8-12 weeks (24, 25). Decreasing this gap to a 
matter of days can decrease the time spent on an ineffective ART regimen or prevent the 
emergence of drug resistance.  
 
Outcomes in the SOC arm were likely better than in a routine care setting because of study-
related retention activities or selection of more compliant participants in research, resulting in an 
underestimate of the positive impact of POC VL testing. Prior review of routine care at 
GHESKIO found 68% of adolescents were retained in care at 12 months (4), less than the 93% 
follow-up achieved in our study (26). Loss and inconsistent HIV care – disengaging and re-
engaging from regular follow-up – is common among adolescents (27-29). Completing VL 
testing over multiple visits risks patient loss before poor outcomes can be identified and 
addressed. While the POC arm may have also achieved more optimal follow-up care as research 
participants, POC VL testing is completed in a single visit making differences in consistency of 





An unexpected benefit of POC testing was improved accuracy of self-reported ART adherence. 
POC participants were more forthcoming about sub-optimal ART adherence, improving the 
accuracy, and thus the utility, of an easy and affordable adherence measurement (30, 31). We 
hypothesize there may be several issues accounting for the more accurate self-reporting. First, 
the study was unblinded, and participants completed an adherence assessment before VL testing. 
POC participants likely anticipated the immediate VL result which would validate their self-
report, and in turn, more honestly reported sub-optimal adherence. Second, a same day VL result 
could have made adherence counseling more personal, less abstract. The VL result was a direct 
indication of the participant’s current VL, having been measured from the blood sample taken 
that day. The counseling message could be centered around “your VL today”, and directly linked 
to negative consequences on health outcomes.  
 
VL outcomes did not differ by arm. This is disappointing and may suggest that our study 
population, 70% of whom acquired HIV perinatally and had been on ART an average of 6 years, 
may experience a combination of drug fatigue and encountering new challenges as they age into 
adolescence that put them at particularly high risk for poor adherence (32-34). Further, the 
proportion of our study population who remained on NNRTI ART regimens may have developed 
resistance and adherence changes alone will not impact VL for those on ineffective regimens. In 
contrast to our findings, the STREAM trial evaluated POC VL testing among adults in South 
Africa receiving their first VL test 6 months after initiating ART, and found that 90% of 
participants achieved a VL <200 copies/mL, compared to 76% of participants receiving standard 
laboratory testing (35). POC VL testing in a less ART-experienced AYA population may result 




We note several limitations. A POC VL test is narrow in scope as an intervention to address 
multi-pronged barriers to poor ART adherence. POC VL testing could be used in concert with 
additional interventions to address diverse challenges. Further, a participant on an ineffective 
drug regimen will not achieve viral suppression even with perfect ART adherence. However, the 
WHO-recommended guidelines for identifying treatment failure once a high VL is detected and 
switching to a second or third line ART regimen is to first provide enhanced adherence 
counseling and establish an accurate adherence measurement. A POC VL test may enable 
clinicians to accurately assess adherence sooner leading to a faster switch to a more effective 
ART drug regimen, if indicated. 
 
In conclusion, POC VL testing was successfully integrated into a low-resource clinical setting 
and was more efficient at returning VL test results. By optimizing an essential HIV health 
service like VL monitoring, particularly for a high-risk population with persistently poor HIV 
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4.7 Figures and Tables 
Figure 4.1: Flow diagram of participant screening, enrollment, and follow-up 
 
 
150 adolescents and youth 
randomized 
 




3 pregnant at enrollment   
3 unable to obtain parental consent 






75 standard care 
(SOC) 
 
75 Included in intent-to-treat analysis 
 69 participants completed study 
 1 participant died 
 5 lost to follow-up 
 
 
75 Included in intent-to-treat analysis 
 72 participants completed study 
 1 participant died 







Table 4.1: Clinical and socio-demographic characteristics of 150 participants ages 10-24 
years enrolled in HIV care at GHESKIO in Port-au-Prince, Haiti 








Characteristics at study enrollment 
Age (N%)     
Range (years) 12-24 14-24 12-24  
Median (IQR) 20 (18-22) 20 (18-21) 19 (18-22) 0.75 
Mean (years (SD)) 19.37 (3.21) 19 (2.64) 19 (2.96) 0.73 
10-14 10 (6.6) 4 (5.3) 6 (8.0) 
0.77 15-19 63 (42.0) 31 (41.3) 32 (42.7) 
20-24 77 (51.3) 40 (53.3) 37 (49.3) 
Sex (male) 60 (40.0) 25 (33.3) 35 (46.7) 0.13 
Weight, kg (mean (SD)) 52.71 (10.68) 52.82 (9.47) 52.61 (11.83) 0.91 
BMI, N(%)     
Mean (SD)) 20.71 (3.57) 20.81 (3.23) 20.61 (3.9) 0.73 
Underweight 29 (19.3) 14 (18.7) 15 (20.0) 
0.78 
Normal 108 (72.0) 53 (70.1) 55 (73.3) 
Overweight 9 (6.0) 6 (8.0) 3 (4.0) 
Obese 4 (2.7) 2 (2.7) 2 (2.7) 
Transmission Route, N(%)     
Behavioral 44 (29.3) 20 (26.7) 24 (32.0) 
0.59 
Perinatal 106 (70.7) 55 (73.3) 51 (68.0) 
ART regimen, N(%)     
NRTI + NNRTIa 77 (51. 3) 40 (53.3) 37 (49.3) 
0.38 NRTI + PI w/boosterb 68 (45.3) 34 (45.3) 34 (45.3) 
NRTI + INSTIc 5 (3.3) 1 (1.3) 4 (5.3) 
Time on ART, N(%)     
Mean (years (SD)) 6.08 (5.47) 6.95 (5.49) 5.51 (4.65) 0.09 
6 months – 2 years 54 (36.0) 25 (33.3) 29 (38.7) 
0.47 
2 to < 5 years 30 (20.0) 15 (20.0) 15 (20.0) 
5 to < 10 years 28 (18.7) 12 (16.0) 16 (21.3) 
> 10 years 38 (25.3) 23 (30.7) 15 (20.0) 
Viral load (copies/mL), N(%)     
<40  60 (40.0) 28 (37.3) 32 (42.7) 
0.56 
41-1000  26 (17.3) 14 (18.7) 12 (16.0) 
1001-50,000 47 (31.3) 22 (29.3) 25 (33.3) 
>50,000 17 (11.3) 11 (14.7) 6 (8.0) 
CD4+ T-cell count within past 3 years 
(cells/mm3), N(%) 
    
Mean(SD)     
<200 25 (16.7) 11 (14.7) 14 (18.7) 
0.19 
200 – 499 42 (28.0) 27 (36.0) 15 (20.0) 
>500   74 (49.3) 33 (44.0) 41 (54.7) 
Value not available  9 ( 6.0)  4 (5.3) 5 (6.6) 
Characteristics at ART Initiation 
Age      
Range (years) 2-24 2-23 4-24  
Median (IQR) 14 (7.25-18) 14 (7-18) 15 (9-18.5) 0.21 
Mean (years (SD)) 13.29 (6.08) 12.63 (6.30) 13.91 (5.79) 0.20 
ART regimen, N(%)     
0.51 NRTI + NNRTId 147 (98.0) 74 (98.7) 73 (97.3) 
NRTI + PI boostere 3 (2.0) 1 (1.3) 2 (2.7) 
CD4+ T-cell count (cells/mm3), N(%)     
Mean (SD) 463.02 (342.30) 459.38 (387.77) 467.27 (284.24) 0.91 
<200 22 (14.6) 13 (17.3) 9 (12.0) 
0.39 200 – 499 46 (30.7) 26 (34.7) 20 (26.7) 
>500 36 (24.0) 17 (22.7) 19 (25.3) 
a Includes AZT/3TC/EFV, AZT/3TC/NVP, TDF/3TC/EFV;  b Includes AZT/3TC//LPV/r, TDF/3TC/ATV/r, TDF/3TC/LPV/r, 
TDF/3TC/AZT/r; c Includes TDF/3TC/DTG; d Includes 3TC/D4T/EFV, 3TC/DDI/EFV, AZT/3TC/ABC, AZT/3TC/EFV, 







Figure 4.2 Association of sub-optimal self-reported ART adherence and VL >1,000 
copies/mL at month 6 
Odds Ratio (95% CI, Log Scale) 
 
Self-reported adherence questions 
 
Responses 
Question 1: In the last 7 days, on how many days did you miss at least 
one dose of any of your ART medicines?  
Sub-optimal defined as >2 
# of days (0-7) 
Question 2: In the last 7 days, how good of a job did you do at taking 
your ART medicine in the way your doctor told you to?  
Sub-optimal defined as <5 
Very poor = 1 
Poor = 2 
Fair = 3 
Good = 4 
Very good = 5 
Question 3: In the last 7 days, how often did you take your ART 
medicine in the way your doctor told you to?  
Sub-optimal defined as <6 
Never = 1 
Rarely = 2 
Sometimes = 3 
Usually = 4 
Almost always = 5 
Always = 6 

















OR: 3.2; 95% CI: 1.1-9.9 
OR: 9.8; 95% CI: 3.4-32.3 
OR: 1.7; 95% CI: 0.6-4.6
 
 OR: 9.8; 95% CI: 3.4-32.3 
OR: 6.4; 95% CI: 2.2-21.9
 
 OR: 9.8; 95% CI: 3.4-32.3 
OR: 1.9; 95% CI: 0.7-5.1
 
 OR: 9.8; 95% CI: 3.4-32.3 
OR: 5.8; 95% CI: 2.1-18.6
 
 OR: 9.8; 95% CI: 3.4-32.3 
OR: 2.6; 95% CI: 0.9-7.4
 
 OR: 9.8; 95% CI: 3.4-32.3 
OR: 6.6; 95% CI: 2.1-25.2
 







Table 4.3: Self-reported ART adherence by randomization arm at month 1 and month 6














Question 1  
Number of doses missed in the last 7 days       
    0-1 46 (61.3) 46 (61.3) 
1.0 
38 (52.8) 50 (72.5) 
0.03 
    2+ 29 (38.7) 29 (38.7) 34 (47.2) 19 (27.5) 
Mean (SD) 1.5 (1.9) 1.4 (1.8) 0.86 2.0 (2.2) 1.0 (1.6) <0.01 
Mean (SD)* 79.2 (26.4) 80.0 (26.1) 0.86 71.83 (31.07) 85.09 (22.6) <0.01 
Median (IQR)* 85.7 (71.4-100) 85.7 (71.4-100) 0.86 85.7 (57.1-100) 100 (71.4-100) <0.01 
Question 2  
In the last 7 days, how good of a job did you do at taking your 
ART in the way your MD told you? 
      
Very good 31 (41.3) 19 (25.3) 
0.06 
31 (43.1) 40 (58.0) 
0.15 
Good/Fair/Poor/Very poor 44 (58.7) 56 (74.7) 41 (56.9) 29 (42.0) 
Mean (SD)* 81.9 (20.1) 77.6 (20.3) 0.20 76.1 (26.14) 87.8 (18.5) <0.01 
Median (IQR)* 80.0 (80.0-100) 80.0 (80.0-90.0) 0.12 80.0 (60.0-100) 100 (80.0-100) <0.01 
Question 3  
In the last 7 days how often did you take your ART medicine in 
the way your MD told you? 
      
Always 29 (38.7) 31 (41.3) 
0.87 
33 (45.8) 41 (59.4) 
0.15 Almost Always/Usually 
Sometimes/Rarely/Never 
46 (61.3) 44 (58.7) 39 (54.2) 28 (40.6) 
Mean (SD)* 81.6 (20.8) 80.2 (22.4) 0.71 78.9 (26.8) 88.4 (18.4) 0.02 
Median (IQR)* 83.3 (66.7-100) 83.3 (66.7-100) 0.78 83.33 (66.7-100) 100 (83.3-100) 0.04 
Composite 3-Question Score  
Mean (SD)* 80.9 (20.5) 79.3 (20.9) 0.63 75.6 (26.6) 87.1 (18.7) <0.01 
Median (IQR)* 83.0 (71.7-93.3) 83.0 (76.9-100) 0.41 83.0 (59.7-100) 94.4 (82.2-100) 0.01 
     




Table 4.4a: Viral load outcomes by randomization arm at month 6 
 Point-of-care  
arm N=75; N (%) 
Standard care 
arm N=75; N (%) 
p-
value 
Month 1    
VL <40 copies/mL 28 (37.3) 32 (42.7) 
0.79 VL 41-1000 copies/mL 14 (18.7) 12 (16.0) 
VL >1,000 copies/mL 33 (44.0) 31 (41.3) 
Month 6      
VL <40 copies/mL 32 (42.7) 35 (46.7) 
0.57 
VL 41-1000 copies/mL 12 (16.0) 8 (10.7) 
VL >1,000 copies/mL 28 (37.3) 26 (34.6) 
VL not measured* 3 (4.0) 6 (8.0) 
Change in VL status between Month 1 and Month 6   
Achieved VL <1,000 copies/mL 11 (14.7) 10 (13.3) 
0.87 
Sustained VL <1,000 copies/mL 33 (44.0) 33 (44.0) 
Viral Rebound** 9 (12.0) 8 (10.7) 
Remained VL >1,000 copies/mL  19 (25.3) 18 (24.0) 
VL not measured at month 6* 3 (4.0) 6 (8.0) 
 
 
Table 4.4b: TDF-DP drug level outcomes by randomization arm and VL among first 62 
participants enrolled at month 6 
 
 Point-of-care  
arm N=31 




TDF-DP f/mol (mean(sd)) 993.8 (942.4) 866.3 (781.7) 0.56 
Dosing, N(%)    
7 doses 6 (19.4) 6 (19.4) 
0.98 
4-6 doses 11 (35.5) 11 (35.5) 
2-3 doses 4 (12.9) 3 (9.7) 
<2 doses 10 (32.2) 11 (35.4) 







TDF-DP f/mol (mean(sd)) 281.7 (373.2) 1286.7 (846.9) <0.01 
Dosing, N(%)    
7 doses 0 (0.0) 12 (30.0) 
<0.01 
4-6 doses 2 (9.1) 20 (50.0) 
2-3 doses 4 (18.2) 3 (7.5) 
<2 doses 16 (72.7) 5 (12.5) 
 
* VL not measured for participants who were lost from follow-up (n=6), died (n=2), or  
withdrew (n=1) from the study before completion 







Supplemental Table 4.1: Study schema comparing study activities and procedures for point-of-care arm versus standard arm 
 
Point-of-care arm Standard care arm 
Month 1 VL Test + Receive Result + Adherence Counseling 
Adherence assessment 
VL knowledge questionnaire (baseline) 
VL Test 
Adherence assessment 
VL knowledge questionnaire (baseline) 
Month 2 VL knowledge questionnaire (follow-up) Receive Result + Adherence Counseling 
Month 3 
 
VL knowledge questionnaire (follow-up) 






Result + Adherence Counseling* 








Receive Result + Adherence Counseling 





Supplemental Table 4.2a: Association of sub-optimal self-reported ART adherence and VL 
>1000 copies/mL at month 6  
 Point-of-care arm Standard care arm 





Number of doses missed in the last 7 days?   
None-1 Ref Ref 
 2+* 9.8 (3.3-32.3) 3.2 (1.1-9.9) 
Question 2 
In the last 7 days, how good of a job did you do at taking you 
ART in the way your MD told you? 
 
Very good Ref Ref 
Good/ Fair/Poor/Very poor* 6.4 (2.2-21.9) 1.7 (0.6-4.6) 
Question 3 
In the last 7 days how often did you take your ART medicine 
in the way your MD told you? 
 
Always Ref Ref 
Almost always/Usually/Sometimes/Rarely/Never* 5.8 (2.1-18.6) 1.9 (0.7-5.1) 
Composite** 
Sub-optimal response to any of the 3 self-reported ART 








Sub-optimal 6.6 (2.1-25.2) 2.6 (0.9-7.4) 
 
Supplemental Table 4.2b: Association of sub-optimal self-reported ART adherence and <4 
doses of TDF per week  
 Point-of-care arm 
OR 
(95% CI) 
Standard care arm 
OR 
(95% CI) 
Question 1   
Number of doses missed in the last 7 days?   
None-1 Ref Ref 
 2+* 28.0 (4.8-262.2) 16.0 (2.3-330.3) 
Question 2   
In the last 7 days, how good of a job did you do at taking you 
ART in the way your MD told you? 
  
Very good Ref Ref 
Good/ Fair/Poor/Very poor* 8.6 (1.7-67.4) 1.8 (0.4-8.1) 
Question 3   
In the last 7 days how often did you take your ART medicine 
in the way your MD told you? 
  
Always Ref Ref 
Almost always/Usually/Sometimes/Rarely/Never* 11.0 (2.1-87.8) 2.4 (0.6-11.0) 
Composite**   
Sub-optimal response to any of the 3 self-reported ART 
adherence related to the past 7 days 
  
Optimal Ref Ref 
Sub-optimal 18.6 (2.7-378.8) 4.6 (1.1-23.3) 
   
*Defined as sub-optimal  




Supplemental Table 4.3: Factors associated with >1000 copies/mL among all participants 
in follow-up at month 6 (N=141) 
  
 VL >1000 copies/mL 
Characteristic OR (95%CI) p-value 
Age 1.0 (0.9-1.1) 0.72 
Age Category   
10-14 1.6 (0.4-6.1) 0.51 
15-19 1.3 (0.6-2.5) 0.51 
20-24 Ref  
Sex (female) 1.0 (0.5-2.0) 0.95 
Transmission Route   
     Behavioral Ref  
     Perinatal 1.8 (0.9-4.0) 0.11 
Time on ART   
6 months – 2 year Ref  
2 to < 5 years 2.9 (1.1-7.4) 0.04 
5 to 10 years 3.8 (1.5-10.3) <0.01 
> 10 years 2.6 (1.1-6.3) 0.04 
Current ART regimen   
NRTI + NNRTI Ref  




Supplemental Table 4.4a: Self-reported ART adherence by HIV transmission among all 
participants at month 6 (N=141)  
 Behavioral Transmission 
N=39 N (%) 
Perinatal Transmission 
N=102 N (%) 
p-value 
Question 1 




    0-1 27 (69.2) 61 (59.8) 
0.40 
    2+ 12 (30.8) 41 (40.2) 
Mean (SD)* 80.22 (31.54) 77.59 (26.63) 0.62 
Median (IQR)* 100.0 (71.43-100.0) 85.71 (71.43-100.0) 0.23 
Question 2 
In the last 7 days, how good of a job did 
you do at taking your ART in the way 
your MD told you? 
   
Very good 21 (53.8) 50 (49.0) 
0.75 
Good/Fair/Poor/Very poor 18 (46.2) 52 (51.0) 
Mean (SD)* 81.54 (26.51) 81.96 (22.25) 0.92 
Median (IQR)* 100.0 (80.00-100.0) 80.00 (65.00-100.0) 0.71 
Question 3 
In the last 7 days how often did you take 
your ART medicine in the way your MD 
told you? 
   
Always 22 (56.4) 52 (51.0) 
0.70 Almost Always/Usually 
Sometimes/Rarely/Never 
17 (43.6) 50 (49.0) 
Mean (SD)* 82.91 (27.17) 83.82 (22.06) 0.84 
Median (IQR)* 100.0 (83.33-100.0) 100.0 (83.33-100.0) 0.68 
Composite 3-Question Score 
Mean (SD)* 81.55 (27.45) 81.13 (22.27) 0.92 
Median (IQR)* 94.44 (78.25-100.0) 88.57 (69.44-100.0) 0.39 
  
Supplemental Table 4.4b: TDF-DP* drug levels by HIV transmission among first 62 
participants at month 6 
 Behavioral Transmission 
N=18 N (%) 
Perinatal Transmission 
N=44 N (%) 
p-value 
TDF f/mol (mean(sd)) 1013.3 (467.5) 896.0 (980.5) 0.63 
Dosing    
   7 doses 3 (16.7) 9 (20.5) 0.06 
   4-6 doses 10 (55.6) 12 (27.3) 
   2-3 doses 3 (16.7) 4 (9.1) 
   <2 doses 2 (11.1) 19 (43.2) 
Dosing    
   >2 doses 16 (88.9) 25 (56.8) 0.03 
   <2 doses 2 (11.1) 19 (43.2) 
a Question responses converted to a standardized score out of 100 







Supplemental Table 4.5: Knowledge of correlation between VL and ART adherence by randomization arm at baseline and one 
month after receiving VL result and adherence counseling* 
 All participants Point-of-care arm Standard care arm 



















For a person’s health, is it better to have a 
high viral load or a low viral load? 
  
    Answered correctly 138 (92.0) 141 (97.2) 71 (94.7) 70 (95.9) 1.0 67 (89.3) 71 (98.6) 0.02 
         
What does a viral load measure?   
    Answered correctly 96 (64.0) 127 (87.6) 46 (61.3) 64 (87.7) <0.01 50 (66.7) 63 (87.5) <0.01 
         
If a patient takes their ART drugs 
correctly, what will happen to their viral 
level? 
  
   Answered correctly 128 (85.3) 134 (92.4) 63 (84.0) 69 (94.5) 0.08 65 (86.7) 65 (90.3) 0.58 
         
If a patient has a viral load test result that 
is <1000, this means: 
  
    Answered correctly  69 (46.0) 113 (77.9) 31 (41.3) 56 (76.7) <0.01 38 (50.7) 57 (79.2) <0.01 
         
Able to describe in own words how ART 












55 (76.4) <0.01 
         
Correctly recalled VL test result 1 month 














         
Greater than 3/5 of questions answered 
correctly 
108 (72.0) 132 (91.0) 54 (72.0) 66 (90.4) <0.01 55 (73.3%) 66 (91.7) <0.01 
*All participants completed the baseline assessment at month 1. Follow-up assessments were administered one month after receipt of the result and adherence counseling, i.e. 




Chapter 5: Conclusion 
5.1 Overview 
The goal of this dissertation was to assess interventions aimed at improving ART adherence 
among adolescents and young adults living with HIV in resource-limited settings. ART 
adherence and subsequent viral suppression are essential for reducing morbidity and mortality, 
and decreasing further HIV transmission. This is particularly important for adolescents and 
young adults for several reasons. First, this age group exhibits worse ART adherence and viral 
suppression outcomes than all other age groups indicating their heightened vulnerability and the 
need for tailored interventions. Second, initiation of sexual activity is common during this 
developmental stage and in the presence of increased sexual risk behaviors, young people 
without a suppressed viral load are at risk for transmitting HIV to sexual partners. Lastly, 
adolescents and young adults have many years of ART ahead of them and so treatment failure 
and drug resistance can have more serious consequences for this population.  
 
First, a systematic review assessed existing interventions, which were conducted among 
adolescents and young adults living in resource-limited settings, and any effects on ART 
adherence outcomes. Second, a randomized control trial was designed and implemented to 
evaluate one such intervention, point-of-care viral load testing, testing the hypothesis that it 
could simplify viral load monitoring, strengthen adherence counseling, and improve ART 
adherence and viral suppression outcomes. A summary of the dissertation findings, strengths and 





5.2 Key Findings 
The systematic review, described in Chapter 2, identified several gaps including: 1) ART 
adherence and viral suppression among adolescents and young adults remains a major challenge 
as only 2 of 7 studies showed any improvement in these outcomes; and 2) interventions targeting 
patient-level barriers, such as text message reminders or individual enhanced adherence 
counseling, may be insufficient as none evidenced improved outcomes. Encouraging 
interventions included two models of HIV care that re-structured how HIV services were 
delivered, specifically those that provided more intense follow-up and added greater oversight to 
standard clinical care by providing home visits or case management. The first, a ‘community-
based support worker’ intervention involved home visits by a lay health worker and found that 5 
years after initiating ART, among adolescents and young adults with a designated community 
support worker, 81.2% achieved a viral load <400 copies/mL compared to 62.8% of those 
without such support (p=0.055). The second, a ‘community adolescent treatment supporter’ 
intervention involved home visits by a peer counselor also living with HIV, found that 12-
months after initiating peer support, 71.8% of adolescents and young adults self-reported optimal 
ART adherence compared to 39.3% of those without such support (p<0.05). Adolescence and 
early adulthood can be a dynamic development period and patient-level barriers may shift, or 
resolve and then re-emerge. Interventions which provide more intensive oversight may be more 
adaptable and thus responsive to unpredictable and diverse barriers.  
 
The study design and protocol details for the randomized control trial to evaluate point-of-care 
viral load testing compared to standard laboratory-based testing are described in Chapter 3. The 




of-care viral load testing – while limiting bias from unknown confounders through 
randomization. The trial was conducted in Haiti to address issues including feasibility and 
increase the likelihood of reproducibility in similar resource-limited settings where the global 
adolescent HIV epidemic is centered. 
 
In Chapter 4, the trial results are reported. Point-of-care viral load testing was effectively 
implemented with 81.8% of test results returned to participants the same day, with a median time 
between blood collection and receipt of the result of 2.7 hours (IQR 2.5-3.2; range 1.7-6.0). 
Ultimately, a greater proportion of participants in the point-of-care arm achieved the primary 
outcome – receipt of the viral load test result within 6 weeks of blood collection – than 
participants in the standard arm (94.7% vs. 80.1% respectively, p<0.01). Point-of-care viral load 
testing reduced the logistical complexity involved in standard laboratory-based testing and gave 
clinicians the ability to identity a majority of participants with a high viral load the same day. 
Even when a point-of-care viral load test result was not available the same day, time to receipt of 
the result was less than the standard arm (7 days (IQR 6-20) vs. 30 days (IQR 28-35)).  
 
Point-of-care viral load testing also appeared to result in more accurate reporting of ART 
adherence. In the point-of-care arm, participants who reported sub-optimal ART adherence were 
more likely to have a viral load >1,000 copies/mL (OR: 6.57; 95% CI: 2.12-25.21), whereas in 
the standard arm, this association was weaker (OR: 2.62; 95% CI: 0.97-7.44). This was further 
supported by an evaluation of tenofovir diphosphate (TDF-DP) drug levels in a subset of 




that there was no real difference in ART adherence. Self-reported ART adherence can be subject 
to recall and social desirability bias, prompting the recommendation of alternative approaches 
which may require additional and more intensive resources such as unannounced pill counts or 
MEMS caps. Establishing ART adherence is a critical step in the viral load monitoring process 
and increasing the accuracy and utility of self-report makes this more feasible, particularly in a 
resource-limited setting.  
 
Viral load outcomes did not differ between arms in our study. We hypothesize the lack of impact 
of point-of-care viral load testing on viral suppression could be due to several factors. First, 
enhanced study-related retention activities, and potential selection of more compliant research 
volunteers, resulted in more consistent retention among participants than has been documented in 
this population in routine care. In a non-study setting, a greater proportion of standard arm 
participants would likely miss follow-up visits when viral load test results are available and 
adherence counseling is provided. Thus our design may have biased against finding a positive 
impact on viral suppression. Secondly, 70% of our study population acquired HIV perinatally 
and had been on ART an average of 6 years. A combination of drug fatigue and encountering 
new challenges as they age into adolescence may put this population at particularly high risk for 
poor ART adherence. Further, a large proportion of our study population remained on NNRTI 
ART regimens and may have developed resistance rendering their treatment ineffective. For 
participants on suboptimal or ineffective ART regimens or who harbored resistance to their 
current regimen, viral load testing and adherence counseling will not impact viral suppression. 





In this dissertation’s proposal, I planned to report the trial results related to the implementation of 
point-of-care testing and the effect on viral load outcomes in one manuscript, and report the 
results of a secondary analysis of the trial data focused on ART adherence in a second 
manuscript. However, one of the primary findings in the trial was the effect of point-of-care 
testing on self-reported ART adherence. ART adherence, as measured by self-report, did not 
differ by arm at baseline, but at month 6, adherence appeared worse among participants in the 
point-of-care arm than in the standard arm. Analyses of the association between self-reported 
ART adherence and both viral load and TDF-DP drug level indicated that adherence was the 
same in both arms, but the point-of-care arm was more forthcoming about sub-optimal 
adherence, more accurately depicting true ART adherence, than the standard arm. Self-report is 
an affordable and easily implemented adherence measurement, and improving its accuracy with 
point-of-care testing is an important finding. Thus, I elected to report all outcomes of the trial 
into one main manuscript.  
 
5.3 Strengths and Limitations 
The point-of-care viral load testing intervention and the analyses presented in this dissertation 
has several limitations. First, point-of-care viral load testing has a limited scope and it is 
optimistic to expect that in isolation, a point-of-care test can have a widespread and sustainable 
impact on ART adherence for adolescents and young adults living with HIV. ART adherence is 
impacted by a plethora of factors outside of the clinical setting including patient-level socio-
economic characteristics, stigma or lack of social support, and/or medication side effects. Our 
primary goal was to assess the implementation of point-of-care testing in a low-resource clinical 




innovate and test an improvement to one aspect of a key HIV health service – viral load 
monitoring. The finding that point-of-care viral load testing increased the efficiency of one step 
in the viral load monitoring process is evidence to advocate for the increased use of this 
intervention, in concert with others which address additional adherence barriers.  
 
Second, an important aspect of the point-of-care testing intervention is the adherence counseling 
guided by the quantitative viral load test result. It can be objectively assessed whether the VL 
test result was available for the counseling session, but the interaction between provider and 
participant is ultimately subjective and will vary according to the participant’s current clinical 
and developmental stage. A curriculum specifically for viral load-informed adherence counseling 
among adolescents living with HIV, developed by ICAP at Columbia University and used in 
several countries in sub-Saharan Africa, was adapted for use in Haiti and included a guided 
check-list of messages and themes for the adherence counseling. Staff were comprehensively 
trained to provide counseling according to this curriculum and complete the guided checklist. 
 
Lastly, an important limitation of any viral load measurement, assessed by a point-of-care or 
standard laboratory-based test, is its inability to distinguish between a high viral load being a 
result of treatment failure in the presence of perfect adherence or of poor adherence alone. A 
participant on an ineffective drug regimen will not achieve viral suppression even with perfect 
ART adherence and routine viral load monitoring. However, the WHO-recommended procedure 
for identifying treatment failure once a high viral load is detected and switching to a second or 




accurate adherence measurement. A point-of-care viral load test could enable a clinician to 
establish an accurate adherence measurement sooner leading to a faster clinical decision about an 
appropriate treatment regimen.  
 
With consideration of these limitations, the dissertation has several strengths. The systematic 
review analyzing existing research on ART adherence among adolescents and young adults 
established there is limited research and a lack of evidence of effective health-services 
interventions implemented in low-and-middle income countries, a critical gap considering this 
population is central to the global HIV epidemic. The randomized control trial results generated 
high quality evidence that point-of-care viral load testing may increase the accuracy, and thus 
utility, of self-report, an affordable and easy-to-use ART adherence measurement. Finally, it 
adds evidence to our knowledge base, that optimizing HIV services to meet the unique, and often 
shifting needs of adolescents and young adults, is feasible and can make measured improvements 
to steps along the HIV care cascade. 
 
5.4 Public Health Impact and Implications for Future Research 
The findings in this dissertation have implications for HIV service delivery for adolescents and 
young adults and can inform future research on interventions to improve ART adherence and 





This dissertation contributes to the public health evidence base on effective HIV service delivery 
interventions implemented among adolescents and young adults in a resource-limited setting. 
The trial results indicate that optimizing one aspect of a key HIV service – viral load monitoring 
– with a point-of-care viral load test can improve the accuracy of ART adherence measurement, 
warranting scale-up of point-of-care testing where possible among adolescents and young adults 
and other similarly vulnerable populations. Where widespread replacement of standard 
laboratory-based tests with a point-of-care test is not immediately feasible, clinics could be 
equipped with the capacity to conduct point-of-care tests in order to prioritize use among 
adolescents or young adults deemed at particularly high risk, as a reasonable first step to routine 
use. In a recent similar study, point-of-care viral load testing among adults newly initiating ART 
showed a significant positive impact on viral suppression compared to standard laboratory-based 
testing, further evidence advocating for routine use of this intervention. 
 
This dissertation also has implications for future research on ART adherence and viral 
suppression among adolescents and young adults. Viral load outcomes remained alarmingly sub-
optimal, and largely unaffected by the point-of-care intervention. Research on repeated use of 
point-of-care testing could result in a greater effect on viral load outcomes with follow-up 
beyond 6 months. Importantly, adolescents’ and young adults’ circumstances evolve and 
associated risk factors will shift similarly. Multiple interventions may be essential to address 
these evolving challenges. Research on point-of-care testing in concert with other interventions 
could elucidate a combination or ‘package’ of interventions effective for improving ART 
adherence and viral suppression. Moving forward in Haiti, this will include incorporating point-




and stigma. Lastly, additional research to address medication-related barriers will be essential. 
More effective ART regimens with low pill burden or injectable formulations, with limited side 
effects are promising.  
 
Lastly, a majority of participants in the trial acquired HIV through perinatal transmission and had 
been living with HIV since birth with many years of experience on ART. This population is 
particularly unique with high risk of drug fatigue, and psychosocial challenges related to 
disclosure to new sexual partners and maintaining the long-term management of their HIV 
disease. Validating findings in other populations, such as adolescents and young adults who 
acquired HIV and initiated ART more recently, would be warranted as their risk factors may 
differ. Point-of-care viral load testing among populations without the complex challenges that 
perinatal-infected adolescents face, may be more likely to positively impact viral load outcomes.   
 
In conclusion, this dissertation identified an effective HIV service delivery intervention to 
improve outcomes among adolescents and young adults living with HIV in a resource-limited 
setting. Point-of-care viral load testing was feasible and efficiently returned test results to 
participants faster than standard laboratory-based testing. Point-of-care viral load testing had no 
effect on viral suppression, but it did improve the accuracy of self-reported ART adherence, an 
important finding that can make viral load monitoring more effective for discerning treatment 
failure from poor adherence among a high risk population and decrease the time needed to make 




on improving HIV outcomes among adolescents and young adults, these findings can inform 
future clinical and implementation research. 
